<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7079862</article-id><article-id pub-id-type="pmid">32040667</article-id><article-id pub-id-type="publisher-id">5943</article-id><article-id pub-id-type="doi">10.1007/s00134-020-05943-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Narrative Review</subject></subj-group></article-categories><title-group><article-title>Critical care management of adults with community-acquired severe respiratory viral infection</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5735-6241</contrib-id><name><surname>Arabi</surname><given-names>Yaseen M.</given-names></name><address><email>Arabi@ngha.med.sa</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>Robert</given-names></name><address><email>rob.fowler@sunnybrook.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hayden</surname><given-names>Frederick G.</given-names></name><address><email>FGH@virginia.edu</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412149.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0608 0662</institution-id><institution>College of Medicine, </institution><institution>King Saud Bin Abdulaziz University for Health Sciences, </institution></institution-wrap>Riyadh, Saudi Arabia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452607.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0580 0891</institution-id><institution>King Abdullah International Medical Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.415254.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1790 7311</institution-id><institution>Intensive Care Department, </institution><institution>King Abdulaziz Medical City, </institution></institution-wrap>P.O. Box 22490, Riyadh, 11426 Saudi Arabia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>Institute of Health Policy Management and Evaluation, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.416745.5</institution-id><institution>Department of Critical Care Medicine, </institution><institution>Sunnybrook Hospital, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.416745.5</institution-id><institution>Department of Medicine, </institution><institution>Sunnybrook Hospital, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.27755.32</institution-id><institution-id institution-id-type="ISNI">0000 0000 9136 933X</institution-id><institution>Department of Medicine, Division of Infectious Diseases and International Health, </institution><institution>University of Virginia School of Medicine, </institution></institution-wrap>Charlottesville, VA USA </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>46</volume><issue>2</issue><fpage>315</fpage><lpage>328</lpage><history><date date-type="received"><day>20</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17&#x02013;53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019 nCoV) are still being identified. Patients with severe RVIs requiring ICU care present typically with hypoxemic respiratory failure. Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza. At present, there are no antiviral therapies of proven efficacy for other severe RVIs. Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs. Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Non-invasive ventilation in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is associated with a high likelihood of transition to invasive ventilation. Limited existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. There is a need for more pragmatic and efficient designs to test different therapeutics both individually and in combination.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s00134-020-05943-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Acute respiratory distress syndrome</kwd><kwd>Influenza</kwd><kwd>Neuraminidase inhibitor</kwd><kwd>Antiviral therapy</kwd><kwd>Coronavirus</kwd><kwd>Antiviral therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Take-home message</title><p id="Par5">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2"><p>Evidence-based supportive care is the mainstay for management of severe respiratory viral infection.</p><p>Early treatment with neuraminidase inhibitors is associated with reduced mortality in severe influenza.</p><p>There is a need for pragmatic and efficient trial designs, to test a variety of investigational therapeutics, individually and in combination.</p></td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par3">With the expanding use of molecular assays, viral pathogens are increasingly detected among critically ill adult patients with respiratory illness; studies have reported a prevalence between 17% and 53% of patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), depending on study design, sample type, duration of illness, and assay methods. Common viruses that can cause severe respiratory viral infections (RVIs) include influenza A and B&#x000a0;viruses, picornaviruses (rhinovirus, enterovirus [e.g., enterovirus D68]), human coronaviruses (229E, NL63, OC43, HKU1), respiratory syncytial virus (RSV), human metapneumovirus, parainfluenza virus, and adenovirus (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). Novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS)&#x000a0;and the 2019 novel coronavirus (2019 nCoV) are still being identified (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Prevalence of community-acquired respiratory viral infections (RVIs) in critically ill patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Population</th><th align="left">Patients (<italic>N</italic>)</th><th align="left">Samples</th><th align="left">Country</th><th align="left">Assays</th><th align="left">Overall prevalence or RVI</th><th align="left">Influenza</th><th align="left">Picornaviruses (rhinovirus, enterovirus)</th><th align="left">Human coronaviruses (229E, NL63, OC43, HKU1)</th><th align="left">Respiratory syncytial virus</th><th align="left">Human metapneumovirus</th><th align="left">Parainfluenza virus</th><th align="left">Adenovirus</th></tr></thead><tbody><tr><td align="left">Daubin 2006</td><td align="left">IMV for&#x02009;&#x0003e;&#x02009;48&#x000a0;h</td><td align="left">187</td><td align="left">TA</td><td align="left">France</td><td align="left">Viral culture, IFA, NAAT</td><td align="left">32 (17%)</td><td align="left">Influenza A 7 (4%)</td><td align="left"><p>Rhinovirus 19 (10%)</p><p>Enterovirus 2 (1%)</p></td><td align="left">1 (0.5%)</td><td align="left">2 (1%)</td><td align="left">0 (0%)</td><td align="left">1 (0.5%)</td><td align="left">1 (0.5%)</td></tr><tr><td align="left">Cameron 2006</td><td align="left">COPD exacerbation requiring NIV or IMV</td><td align="left">105</td><td align="left">PS</td><td align="left">Australia</td><td align="left">IFA, viral culture, NAAT, serology</td><td align="left">46 (43%)</td><td align="left"><p>Influenza A 14 (13%)</p><p>Influenza B 6 (6%)</p></td><td align="left"><p>Rhinovirus 7 (7%)</p><p>Enterovirus 2 (2%)</p></td><td align="left">3 (3%)</td><td align="left">7 (7%)</td><td align="left">3 (3%)</td><td align="left">11 (10%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">Schnell 2014</td><td align="left">Acute respiratory failure</td><td align="left">70, 47 (67%) mechanically ventilated</td><td align="left">PS, BAL</td><td align="left">France</td><td align="left">IFA, NAAT</td><td align="left">34 (49%)</td><td align="left"><p>Influenza A 11 (16%)</p><p>Influenza B 2 (3%)</p></td><td align="left">Rhinovirus 6 (9%)</td><td align="left">5 (7%)</td><td align="left">4 (6%)</td><td align="left">4 (6%)</td><td align="left">1 (1%)</td><td align="left">3 (4%)</td></tr><tr><td align="left">Legoff 2005</td><td align="left">Acute pneumonia admitted to ICU</td><td align="left">41</td><td align="left">BAL</td><td align="left">France</td><td align="left">Viral culture, IFA, NAAT</td><td align="left">13 (32%)</td><td align="left"><p>Influenza A 7 (17%)</p><p>Influenza B 1 (2%)</p></td><td align="left">0 (0%)</td><td align="left">0 (0%)</td><td align="left">2 (5%)</td><td align="left">0 (0%)</td><td align="left">2 (5%)</td><td align="left">2 (5%)</td></tr><tr><td align="left">Wiemken 2013</td><td align="left">Severe CAP admitted to ICU</td><td align="left">468, 84% adults</td><td align="left">PS</td><td align="left">USA</td><td align="left">NAAT</td><td align="left">106 (23%)</td><td align="left">Influenza 38 (8%)</td><td align="left">Rhinovirus 40 (9%)</td><td align="left">0 (0%0</td><td align="left">8 (2%)</td><td align="left">15 (3%)</td><td align="left">4 (1%)</td><td align="left">1 (0.2%)</td></tr><tr><td align="left">Karhu 2014</td><td align="left">Severe CAP</td><td align="left">49</td><td align="left">PS, BAL, TA</td><td align="left">Finland</td><td align="left">NAAT</td><td align="left">24 (49%)</td><td align="left">1 (2%)</td><td align="left"><p>Rhinovirus 15 (30%)</p><p>Enterovirus 2 (4%)</p></td><td align="left">2 (4%)</td><td align="left">1 (2%)</td><td align="left">0 (0%)</td><td align="left">1 (2%)</td><td align="left">4 (8%)</td></tr><tr><td align="left">Tramuto 2016</td><td align="left">ILI admitted to ICU</td><td align="left">233</td><td align="left">PS, BAL</td><td align="left">Italy</td><td align="left">NAAT</td><td align="left">102 (44%)</td><td align="left">57 (24%)</td><td align="left"><p>Rhinovirus 7 (3%)</p><p>Enterovirus 14 (6%)</p></td><td align="left">11 (5%)</td><td align="left">8 (3%)</td><td align="left">16 (7%)</td><td align="left">16 (7%)</td><td align="left">0 (0%)</td></tr><tr><td align="left">Choi 2019<sup>a</sup></td><td align="left">Severe CAP admitted to ICU</td><td align="left">1559</td><td align="left">PS, BAL</td><td align="left">Republic of Korea</td><td align="left">NAAT</td><td align="left">Not reported</td><td align="left">109 (7.0%)</td><td align="left">Rhinovirus 120 (8%)</td><td align="left">56 (4%)</td><td align="left">52 (3%)</td><td align="left">50 (3%)</td><td align="left">71 (5%)</td><td align="left">Not reported</td></tr><tr><td align="left">Shorr 2018</td><td align="left">Severe CAP and HCAP requiring IMV</td><td align="left">364</td><td align="left">sputum, TA, BAL</td><td align="left">USA</td><td align="left">NAAT</td><td align="left">65 (18%)</td><td align="left"><p>Influenza A 12 (3%)</p><p>Influenza B 1 (0.3%)</p></td><td align="left">Rhinovirus/Enterovirus 20 (5%)</td><td align="left">Not reported</td><td align="left">11 (3%)</td><td align="left">8 (2%)</td><td align="left">7 (2%)</td><td align="left">6 (2%)</td></tr><tr><td align="left">Legoff 2018</td><td align="left">Hematology patients admitted to ICU</td><td align="left">747</td><td align="left">PS</td><td align="left">France</td><td align="left">NAAT</td><td align="left">163 (22%)</td><td align="left">20 (3%)</td><td align="left">92 (12%)</td><td align="left">22 (3%)</td><td align="left">18 (2%)</td><td align="left">4 (0.5%),</td><td align="left">12 (2%)</td><td align="left">5 (0.6%)</td></tr><tr><td align="left">Voiriot 2016</td><td align="left">Severe CAP admitted to ICU</td><td align="left">174</td><td align="left">PS, TA, BAL</td><td align="left">France</td><td align="left">NAAT</td><td align="left">93 (53%)</td><td align="left">Influenza A 32 (18%) Influenza B 6 (3%)</td><td align="left">Rhinovirus/Enterovirus 22 (13%)</td><td align="left">14 (8%)</td><td align="left">9 (5%)</td><td align="left">12 (7%)</td><td align="left">3 (2%)</td><td align="left">3 (2%)</td></tr><tr><td align="left">Arabi 2018</td><td align="left">Severe acute respiratory infection admitted to ICU</td><td align="left">222</td><td align="left">PS, TA, BAL</td><td align="left">Saudi Arabia</td><td align="left">NAAT</td><td align="left">43 (19%)</td><td align="left">Influenza A 29 (13%) Influenza B 3 (1%)</td><td align="left"><p>Rhinovirus 9 (4%)</p><p>Enterovirus 0 (0%)</p></td><td align="left">5 (2%)</td><td align="left">1 (0.5%)</td><td align="left">1 (0.5%)</td><td align="left">1 (0.5%)</td><td align="left">1 (0.5%)</td></tr></tbody></table><table-wrap-foot><p>Overall prevalence is reported here for influenza, picornaviruses (rhinovirus, enterovirus), human coronaviruses (229E, NL63, OC43, HKU1), respiratory syncytial virus, human metapneumovirus, parainfluenza virus, and adenovirus. Please refer to the online supplement for references. Studies varied in the approach for sampling and in the used assays; in some studies, specimen collection and assays were standardized across all patients, while in other studies, sampling and assays were performed selectively. All percentages represent % of patients; some patients had more than one viral pathogen isolated</p><p><italic>IMV</italic> invasive mechanical ventilation, <italic>TA</italic> tracheal aspirate, <italic>IFA</italic> immunofluorescence assay, <italic>NAAT</italic> (nucleic acid amplification test) includes commercial and in-house PCR, RT-PCR, and PCR multiplex, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>NIV</italic> non-invasive ventilation, <italic>PS</italic> nasopharyngeal specimen including nasopharyngeal or oropharyngeal aspirates or swabs, <italic>BAL</italic> bronchoalveolar lavage, <italic>CAP</italic> community-acquired pneumonia, <italic>ILI</italic> influenza-like illness, <italic>HCAP</italic> healthcare-associated pneumonia</p><p><sup>a</sup>Multiple publications exist from the same cohort. We included the most recent one (Supplementary references)</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Common and uncommon community-acquired respiratory viruses that may cause severe respiratory viral infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Virus</th><th align="left">Epidemiologic and clinical features</th><th align="left">Additional infection control precautions<sup>a</sup></th></tr></thead><tbody><tr><td align="left" colspan="3"><bold><italic>Common respiratory viruses</italic></bold></td></tr><tr><td align="left">Influenza A and influenza B</td><td align="left"><p>Only influenza type A viruses are known to have caused pandemics</p><p>Currently circulating seasonal influenza A viruses in humans: subtype A(H1N1)pdm09 and A(H3N2) strains</p><p>Currently circulating influenza B viruses: A/Victoria-like, A/Yamagata-like strains</p><p>May be associated with acute myocardial infarction, myocarditis, rhabdomyolysis, acute renal failure, encephalopathy/encephalitis, and other non-pulmonary complications</p></td><td align="left">Droplet</td></tr><tr><td align="left">Picornaviruses (rhinovirus, enterovirus)</td><td align="left" rowspan="6"><p>Frequently detected in critically ill patients with severe acute respiratory infection.</p><p>May cause severe illness in the elderly, persons with co-morbidities including immunosuppression.</p></td><td align="left">Droplet</td></tr><tr><td align="left">Human coronaviruses (229E, NL63, OC43, HKU1)</td><td align="left">Contact</td></tr><tr><td align="left">Respiratory syncytial virus</td><td align="left">Contact</td></tr><tr><td align="left">Human metapneumovirus</td><td align="left">Contact</td></tr><tr><td align="left">Parainfluenza (1-4)</td><td align="left">Contact</td></tr><tr><td align="left">Adenoviruses</td><td align="left">Droplet&#x02009;+&#x02009;contact</td></tr><tr><td align="left" colspan="3"><bold><italic>Uncommon and emerging&#x000a0;viruses</italic></bold></td></tr><tr><td align="left">Avian influenza A/H5N1, A/H5N6, A/H7N9 and other subtypes</td><td align="left"><p>Residence in or travel to Southeast and East Asia</p><p>Exposure to poultry or visit to poultry market</p></td><td align="left">Airborne&#x02009;+&#x02009;contact</td></tr><tr><td align="left">MERS-CoV</td><td align="left"><p>Residence in or travel to the Arabian Peninsula</p><p>Exposure to dromedary camel (in endemic areas)</p><p>Nosocomial transmission risk to other patients&#x000a0;and to healthcare workers</p></td><td align="left">Airborne&#x02009;+&#x02009;contact</td></tr><tr><td align="left">SARS-CoV</td><td align="left"><p>No cases have been reported since 2004</p><p>Nosocomial transmission risk to other patients&#x000a0;and to healthcare workers</p></td><td align="left">Airborne&#x02009;+&#x02009;contact</td></tr><tr><td align="left">2019 Novel coronavirus (2019 nCoV)</td><td align="left">As of February 4, 2020, 20630 cases were reported from China and 23 other countries</td><td align="left">Droplet + contact and wherever possible airborne<sup>b</sup></td></tr><tr><td align="left">Measles<sup>c</sup></td><td align="left"><p>Incomplete vaccination</p><p>Characteristic rash. Progressive giant cell pneumonia without rash may occur in immunocompromised (Hecht&#x02019;s pneumonia)</p></td><td align="left">Airborne</td></tr><tr><td align="left">Hantaviruses (e.g., Sin Nombre, Andes)<sup>c</sup></td><td align="left"><p>Residence in or travel to affected areas of North, Central, or South America</p><p>Exposure to rodent excretions particularly when cleaning buildings</p></td><td align="left">Standard</td></tr><tr><td align="left">Varicella-zoster virus<sup>c</sup></td><td align="left"><p>Incomplete vaccination, pregnancy</p><p>Often with characteristic rash</p></td><td align="left">Airborne&#x02009;+&#x02009;contact</td></tr></tbody></table><table-wrap-foot><p>Please refer to the online supplement for references</p><p>Infection control precautions are based on the Centers for Disease Control and Prevention at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions.html#M">https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions.html#M</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/mers/infection-prevention-control.html">https://www.cdc.gov/coronavirus/mers/infection-prevention-control.html</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/standard-precautions.html">https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/standard-precautions.html,&#x000a0;https://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm </ext-link>(all accessed on Dec 10-2019)</p><p><sup>a</sup>All suspected or confirmed RVIs require minimum of standard precautions. Eye protection is a reasonable addition to droplet isolation&#x000a0;as the ocular route of infection has been documented for several common respiratory viruses</p><p><sup>b</sup>Data on the novel coronavirus are based on the WHO interim report as of February 4, 2020</p><p><sup>c</sup>Other viral pathogens with respiratory routes of acquisition</p></table-wrap-foot></table-wrap></p><p id="Par4">Establishing causation between viruses detected in respiratory specimens and the clinical illness is sometimes difficult, because (1) detection of some agents (e.g., picornaviruses) in the upper respiratory tract may indicate asymptomatic or mild infection, (2) upper respiratory tract samples may be negative despite positive lower respiratory tract ones, and (3) secondary bacterial and less often fungal infections are commonly co-identified [<xref ref-type="bibr" rid="CR1">1</xref>]. However, it is generally believed that most respiratory viruses by themselves can cause severe illness, especially so in the elderly, persons with co-morbidities (particularly immunosuppression), and occasionally in previously healthy persons, in addition to predisposing to secondary infections [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par50">The objective of this narrative review is to outline current knowledge on the management of adults requiring ICU admission for community-acquired severe acute respiratory infection (SARI) due to RVIs. This review focuses on viral pathogens transmitted via the respiratory route. Respiratory infections with other viral pathogens, such as cytomegalovirus and herpes simplex viruses, are not&#x000a0;discussed in this review.</p></sec><sec id="Sec2"><title>Antiviral therapy</title><p id="Par6">Generally available antiviral agents for different RVIs are summarized in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> [<xref ref-type="bibr" rid="CR3">3</xref>]. Very few randomized-controlled trials have been completed in patients hospitalized for severe RVIs; recently completed trials of nitazoxanide in SARI patients and of the RSV inhibitor presatovir in adult RSV patients yielded negative results [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Antiviral therapeutics for influenza&#x000a0;have been studied most extensively and&#x000a0;are discussed briefly below. A number of other antiviral agents for influenza, RSV, and other RVIs are advancing in clinical study [<xref ref-type="bibr" rid="CR6">6</xref>].&#x000a0;Controlled studies of lopinavir/ritonavir combined with interferon-beta in hospitlized MERS patients (NCT02845843) and of lopinavir/ritonavir and interferon-alpha 2b in hospitalized 2019-nCoV patients (ChiCTR2000029308)&#x000a0;are currently in progess.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Antiviral agents for community-acquired respiratory viral infections (RVIs) and relevance to critically ill patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Mechanism of action</th><th align="left">Target Virus</th><th align="left">Resistance</th><th align="left">Formulation</th><th align="left">Applicability to critically ill patients</th></tr></thead><tbody><tr><td align="left">Amantadine</td><td align="left">M2 ion channel blockers</td><td align="left">Influenza A</td><td align="left">High levels of resistance</td><td align="left">Oral</td><td align="left">Not recommended</td></tr><tr><td align="left">Rimantadine</td><td align="left">M2 ion channel blockers</td><td align="left">Influenza A</td><td align="left">High levels of resistance</td><td align="left">Oral</td><td align="left">Not recommended</td></tr><tr><td align="left">Oseltamivir</td><td align="left">Neuraminidase inhibitor(NAI)</td><td align="left">Influenza A and B</td><td align="left">Uncommon (1-3% of circulating isolates) but higher for treatment-emergent in critically ill and immunocompromised</td><td align="left">Oral</td><td align="left"><p>Needs dose adjustment in patients with renal impairment</p><p>No dose adjustment is necessary in patients with mild to moderate hepatic impairment</p><p>Extemporaneous formulation possible or gastric delivery in intubated patients</p></td></tr><tr><td align="left">Zanamivir</td><td align="left">NAI</td><td align="left">Influenza A and B</td><td align="left">Rare</td><td align="left">Intravenous; nebulized solution (investigational); inhaled dry powder (commercial formulation)</td><td align="left"><p>Inhibitory for most strains resistant to oseltamivir</p><p>Nebulized formulation (investigational) with limited use in severely ill patients</p><p>Limited systemic absorption and distribution to extrapulmonary sites of inhaled commercial product</p><p>Lactose-containing powder commercial preparation&#x000a0;with lactose carrier should not be given nebulized as it may cause ventilator circuit obstruction</p><p>Intravenous formulation similar in efficacy to oseltamivir in hospitalized patients.</p><p>Intravenous zanamivir is approved by the European Medicines Agency&#x000a0;(EMA)</p></td></tr><tr><td align="left">Peramivir</td><td align="left">NAI</td><td align="left">Influenza A and B</td><td align="left">Uncommon (see oseltamivir above)</td><td align="left">Intravenous</td><td align="left"><p>Intravenous formulation (multiple doses) similar in efficacy to oseltamivir in hospitalized patients</p><p>Peramivir is approved by the FDA and EMA for uncomplicated influenza</p></td></tr><tr><td align="left">Laninamivir</td><td align="left">NAI</td><td align="left">Influenza A and B</td><td align="left">Rare</td><td align="left">Inhaled, single dose, long acting</td><td align="left"><p>Not suitable for mechanically ventilated patients.</p><p>Approved in Japan only</p></td></tr><tr><td align="left">Favipiravir</td><td align="left">Polymerase inhibitor (PB1 transcriptase), viral mutagen</td><td align="left">Influenza A, B and other RNA viruses</td><td align="left">Not seen in clinical strains</td><td align="left">Oral</td><td align="left"><p>Under study in hospitalized patients in combination with NAIs</p><p>Teratogenicity risk</p><p>PK altered in critically ill with reduced drug exposure&#x02013; appropriate dose regimen uncertain</p><p>Approved only for stockpiling in Japan</p></td></tr><tr><td align="left">Baloxavir</td><td align="left">Polymerase inhibitor (PA cap-dependent endonuclease)</td><td align="left">Influenza A, B</td><td align="left">Treatment-emergence resistance common with monotherapy</td><td align="left">Oral</td><td align="left"><p>Under study (multiple-dose) in combination with NAIs in hospitalized patients</p><p>Not studied and PK uncertain in critically ill patients</p><p>Inhibitory for strains resistant to M2Is and/or NAIs</p><p>At present, baloxavir is approved in the US, Japan, and over eight other countries</p></td></tr><tr><td align="left">Nitazoxanide</td><td align="left">Host-directed and influenza HA</td><td align="left">Influenza and other RVIs</td><td align="left">Not seen in clinical strains</td><td align="left">Oral</td><td align="left">Not effective in hospitalized SARI patients. Not recommended.</td></tr><tr><td align="left">Ribavirin</td><td align="left">Host-directed effects, transcriptase inhibitor, viral mutagen</td><td align="left">RSV, influenza, measles other RVIs</td><td align="left">Not seen in clinical strains</td><td align="left">Aerosolized, oral, intravenous (investigational)</td><td align="left"><p>Aerosol formulation approved in RSV-infected children but of uncertain value.</p><p>All 3 formulations have been used in treating RSV-infected HSCT and SOT patients </p><p>Anecdotal use of systemic ribavirin in severe measles and other paramyxovirus infections</p><p>Not recommended in combination with interferons for MERS</p><p>Teratogenicity risk</p><p>Aerosol delivery presents risk of healthcare worker exposure</p></td></tr><tr><td align="left">Cidofovir</td><td align="left">DNA polymerase inhibitor</td><td align="left">Adenovirus</td><td align="left"/><td align="left">Intravenous</td><td align="left">Anecdotal use in severe adenovirus infections and in immunocompromised patients</td></tr><tr><td align="left">Acyclovir</td><td align="left">DNA polymerase inhibitor</td><td align="left">VZV, HSV</td><td align="left">Uncommon except in immunocompromised</td><td align="left">Intravenous, oral</td><td align="left">Intravenous recommended in VZV pneumonia; addition of systemic corticosteroids recommended by some experts</td></tr></tbody></table><table-wrap-foot><p>Please refer to the online supplement for references</p><p><italic>SARI</italic> severe acute respiratory infection, <italic>RSV</italic> respiratory syncytial virus, <italic>HSCT</italic>&#x000a0;hematopoietic stem-cell transplantation, <italic>SOT </italic>solid-organ transplantation,&#x000a0;<italic>MERS</italic> Middle East Respiratory Syndrome, <italic>VZV</italic> varicella-zoster virus, <italic>HSV</italic> herpes simplex virus, <italic>NAI</italic> neuraminidase inhibitors, <italic>EMA</italic> European Medicines Agency, <italic>FDA</italic> Food and Drug Agency</p></table-wrap-foot></table-wrap></p><sec id="Sec3"><title>Neuraminidase inhibitors</title><p id="Par7">Among the neuraminidase inhibitors (NAIs), oral oseltamivir is the most widely available agent. In an individual participant data meta-analysis of hospitalized patients with influenza A(H1N1)pdm09 virus infection (<italic>n</italic>&#x02009;=&#x02009;29&#x02008;234 patients from 78 studies), NAI treatment (almost exclusively oseltamivir) was associated with a reduction in mortality compared with no treatment, including in the subgroup of ICU patients. Early treatment (within 2&#x000a0;days of symptom onset) was associated with a reduction in mortality compared with later treatment [<xref ref-type="bibr" rid="CR7">7</xref>]. Observational data also indicate reduction in influenza A(H5N1)-associated mortality with timely oseltamivir treatment before the onset of respiratory failure [<xref ref-type="bibr" rid="CR8">8</xref>]. The importance of timing of oseltamivir treatment has been demonstrated in an observational study of 1950 patients admitted to ICUs with influenza A(H1N1)pdm09, which showed a trend toward improved survival for those treated earliest [<xref ref-type="bibr" rid="CR9">9</xref>]. Nevertheless, the Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) recommends oseltamivir for all hospitalized patients with influenza, regardless of illness duration prior to hospitalization [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">In observational studies of critically ill patients with influenza, higher compared to standard doses of oseltamivir did not demonstrate benefit [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. An RCT of standard versus double-dose oseltamivir in hospitalized children and adults found no advantage with respect to virologic and clinical endpoints [<xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, a study demonstrated accumulation of oseltamivir in patients on both extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration leading to 4-to 5-fold increase in plasma levels [<xref ref-type="bibr" rid="CR15">15</xref>]. The IDSA recommends against the routine use of higher doses of US Food and Drug Administration-approved NAI drugs for the treatment of seasonal influenza [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par9">Duration of treatment is traditionally 5&#x000a0;days, but treatment duration is often extended to 10&#x000a0;days for severely ill patients with ARDS or pneumonia or those who are immunocompromised [<xref ref-type="bibr" rid="CR10">10</xref>]. This approach is supported by data showing slow influenza viral clearance from the lower respiratory tract in critically ill patients with influenza A(H1N1)pdm09 [<xref ref-type="bibr" rid="CR16">16</xref>]. Of concern is the recent observation of emergence of oseltamivir resistance in 23% of 22 critically ill A(H1N1)pdm09 patients, and its association with persistent virus detection and much higher mortality [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par10">Nebulized zanamivir solution has been administered to mechanically ventilated patients on compassionate use basis, but the commercial formulation contains lactose and should not be used for nebulization, because its use has been associated with blockage of the ventilator circuit.</p><p id="Par11">Peramivir is the only intravenous influenza antiviral agent currently approved by the US Food and Drug Administration (FDA). Intravenous zanamivir has been recently approved by the European Medicines Agency&#x000a0;(EMA) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). These agents appear to have comparable activity to oseltamivir in hospitalized influenza patients, although one RCT comparing two dose levels of intravenous zanamivir to oral oseltamivir found trends toward shorter illness duration in the subset of ICU patients given higher dose intravenous zanamivir [<xref ref-type="bibr" rid="CR18">18</xref>]. One the other hand, one RCT failed to demonstrate a clinical benefit with intravenous peramivir in hospitalized patients with influenza [<xref ref-type="bibr" rid="CR19">19</xref>]. Because its spectrum of activity includes most oseltamivir-resistant viruses, intravenous zanamivir is indicated for treatment of severe influenza A or B when the patient&#x02019;s influenza virus is known or suspected to be resistant to anti-influenza antivirals other than zanamivir, and/or other antivirals, including inhaled zanamivir, are not suitable (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec4"><title>Baloxavir</title><p id="Par12">Two phase III trials in non-hospitalized patients with influenza found that single-dose baloxavir was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing viral replication [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Baloxavir is inhibitory for strains resistant to current agents. However, high frequencies of emergence of variants with reduced susceptibility have been observed during monotherapy. A double-blind RCT comparing oseltamivir to the combination of oseltamivir and baloxavir is currently in progress in hospitalized patients (NCT03684044). Data on baloxavir&#x02019;s pharmacokinetics and optimal dose regimen in critical influenza illness leading to ICU admission are needed [<xref ref-type="bibr" rid="CR20">20</xref>]. At present, baloxavir is approved in the US, Japan, and over ten other countries.</p></sec></sec><sec id="Sec5"><title>Adjunctive pharmacologic interventions</title><p id="Par13">A wide variety of agents have been proposed for managing immunopathologic host responses that contribute to the pathogenesis of severe RVIs [<xref ref-type="bibr" rid="CR6">6</xref>]. As summarized below, those that have progressed to clinical study include macrolides, corticosteroids, cyclo-oxygenase2 inhibitors, mTOR inhibitors like sirolimus, statins, and high-dose vitamin C. However, until further evidence becomes available, these agents should not be used for managing severe RVIs unless there is another indication or as part of a clinical trial.</p><sec id="Sec6"><title>Macrolides</title><p id="Par14">Macrolide antibiotics, due to putative anti-inflammatory and possible antiviral effects, have been studied in patients with RVIs but with inconsistent results. In an open-label RCT of hospitalized patients with influenza (<italic>n</italic>&#x02009;=&#x02009;107), early combination therapy with clarithromycin, naproxen, and oseltamivir was associated with reduced mortality and hospital length of stay compared to oseltamivir monotherapy [<xref ref-type="bibr" rid="CR22">22</xref>]. On the other hand, in a multicenter observational study (<italic>n</italic>&#x02009;=&#x02009;733), macrolides were not associated with improved survival in critically ill patients with influenza A(H1N1)pdm09 [<xref ref-type="bibr" rid="CR23">23</xref>]. In patients with MERS (<italic>n</italic>&#x02009;=&#x02009;349), macrolide therapy is not associated with a reduction in 90-day mortality or improvement in MERS-CoV RNA clearance [<xref ref-type="bibr" rid="CR24">24</xref>]. A study of clarithromycin combined with the cyclooxygenase inhibitor flufenamic acid in hospitalized patients with influenza is underway (NCT03238612). In addition, macrolides are also examined in one of the domains of the REMAP-CAP trial (Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia, NCT02735707).</p></sec><sec id="Sec7"><title>Corticosteroids</title><p id="Par15">Data on the use of corticosteroids in severe RVIs are largely observational. Several studies demonstrated the association of corticosteroid use with mortality, bacterial and fungal infection and the emergence of antiviral resistance in influenza-associated pneumonia or ARDS [<xref ref-type="bibr" rid="CR25">25</xref>]. A study (<italic>n</italic>&#x02009;=&#x02009;607) that accounted for time-dependent patient-level confounders found no independent influence of corticosteroids on mortality of influenza [<xref ref-type="bibr" rid="CR26">26</xref>]. The IDSA recommends against corticosteroid adjunctive therapy in patients with influenza unless clinically indicated for other reasons [<xref ref-type="bibr" rid="CR10">10</xref>]. In a study of patients hospitalized with RSV (<italic>n</italic>&#x02009;=&#x02009;50), corticosteroid therapy was not associated with significant differences in peak viral load, duration of RSV shedding, nasal cytokines, or lymphocyte subsets, although antibody responses to RSV were slightly blunted [<xref ref-type="bibr" rid="CR27">27</xref>]. In one randomized-controlled trial that included 16 non-ICU SARS patients, &#x0201c;early&#x0201d; (&#x0003c;&#x02009;7&#x000a0;days of illness) hydrocortisone therapy was associated with a higher subsequent plasma viral load [<xref ref-type="bibr" rid="CR28">28</xref>]. In a study on MERS patients (<italic>n</italic>&#x02009;=&#x02009;309), corticosteroid therapy was not associated with significant change in 90-day mortality after adjustment for time-varying confounders, but was associated with delayed MERS-CoV RNA clearance [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec8"><title>Cyclooxygenase-2 inhibitors</title><p id="Par16">Cyclooxygenase-2 may modulate excessive pro-inflammatory responses in severe influenza [<xref ref-type="bibr" rid="CR30">30</xref>]. In addition to the above study of naproxen&#x02013;clarithromycin added to oseltamivir [<xref ref-type="bibr" rid="CR23">23</xref>], preliminary results from a RCT (<italic>n</italic>&#x02009;=&#x02009;120) showed that the combination of celecoxib-oseltamivir compared to oseltamivir alone reduced mortality and cytokine levels, although not viral titers, in hospitalized influenza A(H3N2) patients without increased adverse effects [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec9"><title>Sirolimus</title><p id="Par17">Inhibitors of the mTOR pathway like sirolimus combined with oseltamivir have shown inconsistent effects in murine models of severe influenza [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Sirolimus also can modulate inflammatory responses through its immunosuppressive properties [<xref ref-type="bibr" rid="CR34">34</xref>]. In a small RCT (<italic>n</italic>&#x02009;=&#x02009;28), treatment with sirolimus compared to no sirolimus in patients with influenza A(H1N1) pneumonia receiving invasive mechanical ventilation (in addition to oseltamivir and corticosteroids) resulted in improvement in hypoxia, multiple organ dysfunction and virus clearance, and in shorter duration of mechanical ventilation [<xref ref-type="bibr" rid="CR34">34</xref>]. Further study of sirolimus without systemic corticosteroids is planned among patients hospitalized with influenza (NCT03901001).</p></sec><sec id="Sec10"><title>Statins</title><p id="Par18">Because of the putative anti-inflammatory effects, statins have been proposed as adjunctive therapy in influenza (NCT02056340), although large clinical trials in patients in ARDS have not demonstrated clinical benefit [<xref ref-type="bibr" rid="CR35">35</xref>]. A secondary analysis of data from RCTs using latent class analysis suggested that patients with ARDS may be classified into hyper-inflammatory and hypo-inflammatory subphenotypes, and treatment with simvastatin compared to placebo was associated with improved survival in the hyper-inflammatory but not in the hypo-inflammatory subphenotype [<xref ref-type="bibr" rid="CR36">36</xref>]. Further studies are needed to examine whether adjunctive pharmacologic interventions would be beneficial in targeted subphenotypes of severe RVI.</p></sec><sec id="Sec11"><title>Immune therapy</title><p id="Par19">Studies in which various antibody immunotherapies have been added to neuraminidase inhibitor treatment in hospitalized influenza patients have yielded inconsistent results. A small randomized-controlled trial (<italic>n</italic>&#x02009;=&#x02009;35) demonstrated that treatment of severe influenza A(H1N1)pdm09 patients with hyperimmune globulin (H-IVIG) containing high titers of virus-specific neutralizing antibodies within 5&#x000a0;days of symptom onset was associated with a lower viral load and reduced mortality compared to low-titer IVIG [<xref ref-type="bibr" rid="CR37">37</xref>]. Two recent phase III trials have been completed in seasonal influenza patients. The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [<xref ref-type="bibr" rid="CR38">38</xref>]. The second trial of high-titer versus low-titer anti-influenza immune plasma was terminated for futility because of the lack of effect on the same primary outcome [<xref ref-type="bibr" rid="CR39">39</xref>]. A placebo-controlled, randomized trial of the anti-hemagglutinin stem monoclonal antibody MHAA4549A did not demonstrate benefit over oseltamivir alone [<xref ref-type="bibr" rid="CR6">6</xref>]. The results from these recent trials suggest that polyclonal antibody therapies may not significantly improve outcomes in severe seasonal influenza A, although their possible value in treating severe RVI by novel influenza strains remains to be determined.</p></sec><sec id="Sec12"><title>Vitamin C</title><p id="Par20">The recent CITRIS-ALI trial demonstrated that 96-h infusion of vitamin C compared with placebo in a relatively small number (<italic>n</italic>&#x02009;=&#x02009;167) of patients with sepsis and ARDS did not improve the primary outcome of organ dysfunction scores or alter markers of inflammation and vascular injury. However, mortality, which was one of the forty-six pre-specified secondary endpoints, was significantly lower with vitamin C [<xref ref-type="bibr" rid="CR40">40</xref>]. Results of other ongoing larger trials are awaited, and data on severe RVI are needed.</p></sec></sec><sec id="Sec13"><title>Antibacterial therapy</title><p id="Par21">Co-infections with bacterial pathogens occur often with RVI. Co-infection with <italic>Staphylococcus aureus</italic> is common with influenza pneumonia and can be especially virulent [<xref ref-type="bibr" rid="CR10">10</xref>]. The recent 2019 ATS/IDSA clinical practice guidelines recommend standard antibacterial therapy to be initially prescribed for adults with community-acquired pneumonia who test positive for influenza [<xref ref-type="bibr" rid="CR10">10</xref>]. The guidelines provide details on when to consider empiric therapy for methicillin resistant <italic>Staphylococcus aureus</italic> and <italic>Pseudomonas aeruginosa</italic> and provide guidance for de-escalation of antibacterial therapy in patients with confirmed influenza [<xref ref-type="bibr" rid="CR10">10</xref>]. Clinicians should be aware of the reports of invasive pulmonary aspergillosis in severely ill influenza patients especially those with underlying conditions or receiving corticosteroids, although up to 30% of patients with influenza-associated aspergillosis had been previously healthy [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec14"><title>Supportive care</title><p id="Par22">Patients with severe RVI present typically with pneumonia, acute respiratory distress syndrome (ARDS), decompensated heart failure, or exacerbation of chronic lung disease; leading frequently to acute hypoxemic, and less commonly hypercapnic, respiratory failure. Except for several influenza and novel coronavirus studies noted below, most of the data regarding supportive care strategies come from studies that have not documented specific RVIs. In many ARDS trials, patients with pneumonia constituted a majority of enrolled patients; but detailed description of etiologic pathogens is often lacking. Given the high prevalence of viral pathogens as outlined earlier, it is likely that severe RVIs constitute a considerable proportion. There are general pathophysiologic and clinical similarities between ARDS and pneumonia caused by severe RVIs and those due to other pathogens or etiologies, and therefore, the extrapolation of findings from unselected populations to patients with severe RVIs can be justified in the absence of specific data. At the same time, there are important differences that may lead to heterogeneity in response to treatment.</p><sec id="Sec15"><title>Non-invasive ventilation</title><p id="Par23">Data on non-invasive ventilation (NIV) in severe RVI are limited. In patients with severe RVI resulting in chronic obstructive pulmonary disease (COPD) exacerbations or cardiogenic pulmonary edema, NIV may be effective in reducing the need of endotracheal intubation and decreasing ventilator-associated complications and mortality [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par24">However, NIV in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is of uncertain benefit. Observational studies reported variable results for NIV in patients with severe influenza A(H1N1)pdm09 with some reporting NIV failure in up to 85% [<xref ref-type="bibr" rid="CR43">43</xref>]. In one multicenter observational study of 1898 critically ill patients with acute hypoxemic respiratory failure due to influenza, 806 underwent initial NIV, and 56.8% of them required conversion to invasive ventilation. Patients with SOFA&#x02009;&#x02265;&#x02009;5 had a higher risk of NIV failure. Similar to other studies, NIV failure was associated with increased ICU mortality compared with invasive mechanical ventilation [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par25">Data from uncontrolled studies suggested that NIV might have been effective and safe in the management of some patients with SARS [<xref ref-type="bibr" rid="CR45">45</xref>], while others highlighted concerns of increased SARS transmission risk to healthcare workers [<xref ref-type="bibr" rid="CR46">46</xref>]. In a multicenter cohort of 302 MERS critically ill patients, NIV was used initially in 35% of patients, but the vast majority of them (92.4%) required conversion to invasive mechanical ventilation; however, NIV was not independently associated with 90-day mortality [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par26">A recent single-center RCT in patients with unselected patients with ARDS (<italic>n</italic>&#x02009;=&#x02009;83, 45% pneumonia) showed that treatment with helmet NIV resulted in significant reduction of intubation rates and in 90-day mortality [<xref ref-type="bibr" rid="CR48">48</xref>]. Further studies in patients with severe RVI are needed, as helmet NIV may be more effective than traditional masks and may be associated with less risk of transmission due to aerosol generation.</p><p id="Par27">Based on available evidence, NIV in severe RVI may be used in selected patients in early stages and milder forms of acute hypoxemic respiratory failure, excluding those in shock or multiorgan failure, with the recognition that for patients who do not show signs of early recovery, NIV may well delay but not avoid invasive ventilation [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec><sec id="Sec16"><title>High-flow nasal cannula</title><p id="Par28">High-flow nasal cannula has emerged as an alternative to NIV to prevent intubation in patients with acute hypoxemic respiratory failure. In one trial (<italic>n</italic>&#x02009;=&#x02009;310, 72% community-acquired pneumonia), treatment with high-flow oxygen, standard oxygen, or NIV did not result in significantly different intubation rates; however, there was a significant difference in favor of high-flow nasal cannula in 90-day mortality [<xref ref-type="bibr" rid="CR49">49</xref>]. A small cohort of patients with severe RVI with influenza A(H1N1)pdm09 (<italic>n</italic>&#x02009;=&#x02009;25) showed that high-flow nasal cannula was associated with avoidance of intubation in 45% of patients, although almost all patients with higher severity of illness and shock were eventually intubated [<xref ref-type="bibr" rid="CR50">50</xref>].</p></sec><sec id="Sec17"><title>Invasive ventilation</title><p id="Par29">Based on current evidence, patients with ARDS due to severe RVI should be managed with lung-protective strategy with low tidal volumes (6&#x000a0;ml/kg predicted body weight) and plateau pressures&#x02009;&#x0003c;&#x02009;30 to 35 cmH<sub>2</sub>O. In adults with acute lung injury or ARDS due to various causes, an individual patient data meta-analysis of 2299 patients from three trials (50% with pneumonia) found that higher positive end-expiratory pressure (PEEP) levels were associated with improved survival among the subgroup of patients with ARDS (defined by PaO<sub>2</sub>/FiO<sub>2</sub>&#x02009;&#x02264;&#x02009;200&#x000a0;mmHg) [<xref ref-type="bibr" rid="CR51">51</xref>]. A recent RCT of over 1000 patients with moderate-to-severe ARDS (55% with pneumonia) demonstrated that prolonged and high-pressure recruitment maneuvers was associated with increased 28-day mortality [<xref ref-type="bibr" rid="CR52">52</xref>]. Titration of PEEP to achieve optimal oxygenation, perhaps without aggressive recruitment maneuvers, remains a reasonable strategy for most patients.</p></sec><sec id="Sec18"><title>High-frequency oscillatory ventilation (HFOV)</title><p id="Par30">HFOV ventilates the lung with tidal volumes lower than anatomical dead space while achieving relatively high mean airway pressures [<xref ref-type="bibr" rid="CR53">53</xref>]. In patients with influenza A(H1N1)pdm09 influenza, HFOV has been used as a rescue therapy for those not responding to conventional ventilation [<xref ref-type="bibr" rid="CR53">53</xref>]. Two randomized clinical trials showed that HFOV in moderate-to-severe ARDS was not associated with improved outcomes compared to conventional ventilation [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. However, a meta-analysis of 1552 patients (55% with pneumonia) found that the HFOV treatment effect depended on baseline severity of hypoxemia, with harm&#x000a0;among patients with mild-moderate ARDS but possibly decreased mortality in patients with very severe ARDS [<xref ref-type="bibr" rid="CR56">56</xref>].&#x000a0;Therefore, while HFOV is not recommended for routine use in ARDS, there may still be a role as rescue therapy [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec19"><title>Prone positioning</title><p id="Par31">A multicenter RCT (<italic>n</italic>&#x02009;=&#x02009;474, 60% with pneumonia) demonstrated that early application of prone positioning (at least 16&#x000a0;h per session) in patients with severe ARDS (PaO<sub>2</sub>/FiO<sub>2</sub>&#x02009;&#x0003c;&#x02009;150&#x000a0;mmHg, with an FiO<sub>2</sub>&#x02009;&#x02265;&#x02009;0.6, PEEP of&#x02009;&#x02265;&#x02009;5 cmH<sub>2</sub>O, and a tidal volume close to 6&#x000a0;ml/kg predicted body weight) resulted in decreased mortality [<xref ref-type="bibr" rid="CR57">57</xref>]. Prone positioning in patients with avian A(H7N9) influenza-related severe ARDS has been associated with improved oxygenation, sustained after returning to a supine position, and with decreased carbon dioxide retention [<xref ref-type="bibr" rid="CR58">58</xref>].</p></sec><sec id="Sec20"><title>Neuromuscular blockers</title><p id="Par32">In patients with severe ARDS, in one trial (<italic>n</italic>&#x02009;=&#x02009;339, 38% community-acquired pneumonia), early administration of a neuromuscular blocking agent improved the adjusted 90-day survival and increased the time off the ventilator without increasing muscle weakness [<xref ref-type="bibr" rid="CR59">59</xref>]. However, in a recent larger trial that enrolled patients with moderate-to-severe ARDS (<italic>n</italic>&#x02009;=&#x02009;1006, 59% pneumonia), treated with a strategy involving high PEEP, there was no significant difference in mortality at 90&#x000a0;days between patients who received an early, continuous cisatracurium infusion and those who were treated with a usual-care approach with lighter sedation targets [<xref ref-type="bibr" rid="CR60">60</xref>]. Specific data on neuromuscular blockade in severe RVI are lacking.</p></sec><sec id="Sec21"><title>Extracorporeal membrane oxygenation (ECMO)</title><p id="Par33">The latest RCT for ECMO (EOLIA) included 249 patients with severe ARDS, 18% with viral etiologies, and found that ECMO did not reduce mortality at day 60 [<xref ref-type="bibr" rid="CR61">61</xref>]. Yet, a post hoc Bayesian analysis found that the interpretation of benefit versus no benefit in this trial is critically dependent upon the range of prior assumptions reflecting varying degrees of skepticism and enthusiasm of previous evidence for the benefit of ECMO&#x02014;clinicians with more enthusiasm for the benefit of ECMO may be justified in considering it for certain patients [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par34">Indeed, observational studies reported lower hospital mortality among patients with ARDS related to influenza A(H1N1)pdm09 with transfer to an ECMO center compared with matched non-ECMO-referred patients [<xref ref-type="bibr" rid="CR63">63</xref>]. A case&#x02013;control study also suggested survival benefit for ECMO in patients with severe MERS [<xref ref-type="bibr" rid="CR64">64</xref>]. ECMO is likely to be associated with better outcomes when used among patients with limited organ failures and good premorbid functional status, and should be considered for patients who fail other evidence-based oxygenation strategies according to individual patient characteristics and a potential risk&#x02013;benefit determination.</p></sec><sec id="Sec22"><title>Cardiovascular management</title><p id="Par35">Timely adequate fluid resuscitation is an essential element of the management of patients with severe RVI and shock. However, in those with ARDS (<italic>n</italic>&#x02009;=&#x02009;1000, 47% pneumonia), a conservative strategy of fluid management improved lung function and shortened the duration of mechanical ventilation without increasing non-pulmonary-organ failures [<xref ref-type="bibr" rid="CR65">65</xref>]. In addition, aggressive fluid administration may worsen ventricular function. This may be particularly relevant for patients with severe RVI. Myocardial involvement is not uncommon with severe influenza A or B virus infection, and multiple studies have shown an association between influenza and acute myocardial infection and myocarditis [<xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. Echocardiographic findings often include right- and left-ventricular dysfunction [<xref ref-type="bibr" rid="CR66">66</xref>]. Therefore, clinical assessment of fluid responsiveness is important along with quantification of right- and left-ventricular size and function using echocardiography and/or dynamic minimally invasive cardiovascular monitoring, if available. Myocarditis has associated with longer duration of vasoactive agents and mortality and may sometimes require ECMO or other types of supportive care [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p></sec><sec id="Sec23"><title>Infection prevention and control</title><p id="Par36">Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> summarizes infection control precautions for different RVIs as recommended by the Centers for Disease Control and Prevention (please refer to Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> footnote for CDC references). In patients presenting with severe RVIs, contact plus droplet precautions are recommended; droplet precautions may be discontinued when adenovirus and influenza have been ruled out. For patients with a history of recent travel (10&#x02013;21&#x000a0;days) to countries with active outbreaks of SARS, MERS, or avian influenza, airborne plus contact precautions and eye protection are recommended.</p><p id="Par37">Aerosol-generating procedures, such as bronchoscopy, endotracheal intubation, and open suctioning of the respiratory tract, tracheotomy, manual ventilation before intubation, nebulizer treatment, high-flow nasal cannula, non-invasive ventilation, and chest compressions, have been implicated with transmission of infectious agents to healthcare personnel. However, these findings were identified from limited studies, mainly during the SARS outbreak [<xref ref-type="bibr" rid="CR71">71</xref>]. Nevertheless, it is recommended during aerosol-generating procedures on patients with suspected or proven infections transmitted by aerosols (for example influenza, MERS, SARS) to wear a fit-tested N95 mask in addition to gloves, gown, and face/eye protection. Closed-circuit suctioning may reduce the exposure to aerosols. Performing these procedures in an airborne isolation room when feasible is recommended.</p><p id="Par38">RCTs comparing N95 respirators to medical masks in health care personnel working in outpatient and ward settings have not shown significant differences in protection from laboratory-confirmed influenza or other RVIs [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. The relevance of these observations to the ICU setting is uncertain, given the frequent use of aerosol-generating procedures in critically ill patients. Cloth masks are clearly inferior to medical masks in protecting HCWs from RVIs [<xref ref-type="bibr" rid="CR74">74</xref>]. Other aspects of prevention strategies to prevent transmission when caring for patients with severe RVIs include annual influenza vaccination of healthcare workers, adherence to standard precautions, including hand hygiene, during the care of any patient and appropriate management of ill healthcare workers (please refer to Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> footnote for CDC references). Recently, antiseptic hand rubbing using ethanol-based disinfectants (EBDs) was found to be less effective than hand washing with running water in inactivating influenza virus in undried mucus under experimental conditions; [<xref ref-type="bibr" rid="CR75">75</xref>] also nonenveloped viruses like adenovirus which are not easily inactivated by EBDs. The implications of these observations for clinical practice remain to be determined but hand washing with soap and water or hand rubbing with EBD for longer than 30&#x000a0;s may be warranted.</p></sec></sec><sec id="Sec24"><title>Future directions for research</title><p id="Par39">The Global Influenza Programme has published the updated WHO Public Health Research Agenda for Influenza, in which research priorities were identified for several domains including patient management [<xref ref-type="bibr" rid="CR76">76</xref>]. Existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. Data on supportive management in resource-restricted settings are severely lacking. There is a need for more pragmatic and efficient designs to test antiviral therapeutics, individually and in combination in patients with severe RVI who are at increased risk for complications from both the disease and treatments. Adaptive randomized-controlled trial that tests several treatments, such as the REMAP-CAP trial (NCT02735707), may represent an efficient approach.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec25"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="134_2020_5943_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 21&#x000a0;kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflicts of interest</title><p id="Par40">Dr. Arabi is the principal investigator on a clinical trial for lopinavir/ritonavir and interferon in Middle East respiratory syndrome (MERS) and that he was a non-paid consultant on antiviral active for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. Dr. Hayden&#x02019;s institution received funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT), and Vaccitech (DSMB chair for influenza RCTs); he received honoraria from World Health Organization (consultant on influenza and emerging viral infections) and the University of Alabama (Scientific Advisory Board member for National Institutes of Health-sponsored Antiviral Discovery and Development Consortium); he disclosed that he has been a non-paid consultant on antivirals active for MERS-CoV for Gilead Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on influenza therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable contributions to the Ford Haitian Orphanage and School for his consulting time; Shionogi and Roche have provided meeting travel support.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karhu</surname><given-names>J</given-names></name><name><surname>Ala-Kokko</surname><given-names>TI</given-names></name><name><surname>Vuorinen</surname><given-names>T</given-names></name><name><surname>Ohtonen</surname><given-names>P</given-names></name><name><surname>Syrjala</surname><given-names>H</given-names></name></person-group><article-title>Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia</article-title><source>Clin Infect Dis</source><year>2014</year><volume>59</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu237</pub-id><?supplied-pmid 24729498?><pub-id pub-id-type="pmid">24729498</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasvold</surname><given-names>J</given-names></name><name><surname>Sjoding</surname><given-names>M</given-names></name><name><surname>Pohl</surname><given-names>K</given-names></name><name><surname>Cooke</surname><given-names>C</given-names></name><name><surname>Hyzy</surname><given-names>RC</given-names></name></person-group><article-title>The role of human metapneumovirus in the critically ill adult patient</article-title><source>J Crit Care</source><year>2016</year><volume>31</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2015.09.035</pub-id><?supplied-pmid 26572580?><pub-id pub-id-type="pmid">26572580</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name><name><surname>Bates</surname><given-names>M</given-names></name><name><surname>Mwaba</surname><given-names>P</given-names></name><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Denning</surname><given-names>DW</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name></person-group><article-title>Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><fpage>1136</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70828-X</pub-id><?supplied-pmid 25189352?><pub-id pub-id-type="pmid">25189352</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Hanfelt-Goade D, Maimon N, Nimer A, et al A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral rsv fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults American Thoracic Society 2018 international conference, San Diego, 2018: abstract A4457</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamino-Arroyo</surname><given-names>AE</given-names></name><name><surname>Guerrero</surname><given-names>ML</given-names></name><name><surname>McCarthy</surname><given-names>S</given-names></name><name><surname>Ramirez-Venegas</surname><given-names>A</given-names></name><name><surname>Llamosas-Gallardo</surname><given-names>B</given-names></name><name><surname>Galindo-Fraga</surname><given-names>A</given-names></name><name><surname>Moreno-Espinosa</surname><given-names>S</given-names></name><name><surname>Roldan-Aragon</surname><given-names>Y</given-names></name><name><surname>Araujo-Melendez</surname><given-names>J</given-names></name><name><surname>Hunsberger</surname><given-names>S</given-names></name><name><surname>Ibarra-Gonzalez</surname><given-names>V</given-names></name><name><surname>Martinez-Lopez</surname><given-names>J</given-names></name><name><surname>Garcia-Andrade</surname><given-names>LA</given-names></name><name><surname>Kapushoc</surname><given-names>H</given-names></name><name><surname>Holley</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name><surname>Smolskis</surname><given-names>MC</given-names></name><name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><collab>Mexico Emerging Infectious Diseases Clinical Research N</collab></person-group><article-title>Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness</article-title><source>Clin Infect Dis</source><year>2019</year><volume>69</volume><fpage>1903</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz100</pub-id><?supplied-pmid 30753384?><pub-id pub-id-type="pmid">30753384</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Nam</surname><given-names>HH</given-names></name><name><surname>Adams</surname><given-names>PL</given-names></name><name><surname>Krafft</surname><given-names>A</given-names></name><name><surname>Ince</surname><given-names>WL</given-names></name><name><surname>El-Kamary</surname><given-names>SS</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name></person-group><article-title>Advances in respiratory virus therapeutics&#x02014;a meeting report from the 6th isirv Antiviral Group conference</article-title><source>Antiviral Res</source><year>2019</year><volume>167</volume><fpage>45</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.04.006</pub-id><?supplied-pmid 30974127?><pub-id pub-id-type="pmid">30974127</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthuri</surname><given-names>SG</given-names></name><name><surname>Venkatesan</surname><given-names>S</given-names></name><name><surname>Myles</surname><given-names>PR</given-names></name><name><surname>Leonardi-Bee</surname><given-names>J</given-names></name><name><surname>Al Khuwaitir</surname><given-names>TS</given-names></name><name><surname>Al Mamun</surname><given-names>A</given-names></name><name><surname>Anovadiya</surname><given-names>AP</given-names></name><name><surname>Azziz-Baumgartner</surname><given-names>E</given-names></name><name><surname>Baez</surname><given-names>C</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Beovic</surname><given-names>B</given-names></name><name><surname>Bertisch</surname><given-names>B</given-names></name><name><surname>Bonmarin</surname><given-names>I</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name><name><surname>Borja-Aburto</surname><given-names>VH</given-names></name><name><surname>Burgmann</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Carratala</surname><given-names>J</given-names></name><name><surname>Denholm</surname><given-names>JT</given-names></name><name><surname>Dominguez</surname><given-names>SR</given-names></name><name><surname>Duarte</surname><given-names>PA</given-names></name><name><surname>Dubnov-Raz</surname><given-names>G</given-names></name><name><surname>Echavarria</surname><given-names>M</given-names></name><name><surname>Fanella</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Gerardin</surname><given-names>P</given-names></name><name><surname>Giannella</surname><given-names>M</given-names></name><name><surname>Gubbels</surname><given-names>S</given-names></name><name><surname>Herberg</surname><given-names>J</given-names></name><name><surname>Iglesias</surname><given-names>AL</given-names></name><name><surname>Hoger</surname><given-names>PH</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Islam</surname><given-names>QT</given-names></name><name><surname>Jimenez</surname><given-names>MF</given-names></name><name><surname>Kandeel</surname><given-names>A</given-names></name><name><surname>Keijzers</surname><given-names>G</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Knight</surname><given-names>M</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Kusznierz</surname><given-names>G</given-names></name><name><surname>Kuzman</surname><given-names>I</given-names></name><name><surname>Kwan</surname><given-names>AM</given-names></name><name><surname>Amine</surname><given-names>IL</given-names></name><name><surname>Langenegger</surname><given-names>E</given-names></name><name><surname>Lankarani</surname><given-names>KB</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name><name><surname>Linko</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Madanat</surname><given-names>F</given-names></name><name><surname>Mayo-Montero</surname><given-names>E</given-names></name><name><surname>McGeer</surname><given-names>A</given-names></name><name><surname>Memish</surname><given-names>Z</given-names></name><name><surname>Metan</surname><given-names>G</given-names></name><name><surname>Mickiene</surname><given-names>A</given-names></name><name><surname>Mikic</surname><given-names>D</given-names></name><name><surname>Mohn</surname><given-names>KG</given-names></name><name><surname>Moradi</surname><given-names>A</given-names></name><name><surname>Nymadawa</surname><given-names>P</given-names></name><name><surname>Oliva</surname><given-names>ME</given-names></name><name><surname>Ozkan</surname><given-names>M</given-names></name><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Rath</surname><given-names>BA</given-names></name><name><surname>Rodriguez</surname><given-names>AH</given-names></name><name><surname>Sarrouf</surname><given-names>EB</given-names></name><name><surname>Seale</surname><given-names>AC</given-names></name><name><surname>Sertogullarindan</surname><given-names>B</given-names></name><name><surname>Siqueira</surname><given-names>MM</given-names></name><name><surname>Skret-Magierlo</surname><given-names>J</given-names></name><name><surname>Stephan</surname><given-names>F</given-names></name><name><surname>Talarek</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>JW</given-names></name><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Torun</surname><given-names>SH</given-names></name><name><surname>Tran</surname><given-names>D</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Van Zwol</surname><given-names>A</given-names></name><name><surname>Vaudry</surname><given-names>W</given-names></name><name><surname>Vidmar</surname><given-names>T</given-names></name><name><surname>Yokota</surname><given-names>RT</given-names></name><name><surname>Zarogoulidis</surname><given-names>P</given-names></name><name><surname>Investigators</surname><given-names>PC</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>JS</given-names></name></person-group><article-title>Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data</article-title><source>Lancet Respir Med</source><year>2014</year><volume>2</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70041-4</pub-id><?supplied-pmid 6637757?><pub-id pub-id-type="pmid">24815805</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adisasmito</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Oner</surname><given-names>AF</given-names></name><name><surname>Gasimov</surname><given-names>V</given-names></name><name><surname>Aghayev</surname><given-names>F</given-names></name><name><surname>Zaman</surname><given-names>M</given-names></name><name><surname>Bamgboye</surname><given-names>E</given-names></name><name><surname>Dogan</surname><given-names>N</given-names></name><name><surname>Coker</surname><given-names>R</given-names></name><name><surname>Starzyk</surname><given-names>K</given-names></name><name><surname>Dreyer</surname><given-names>NA</given-names></name><name><surname>Toovey</surname><given-names>S</given-names></name></person-group><article-title>Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry</article-title><source>J Infect Dis</source><year>2010</year><volume>202</volume><fpage>1154</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1086/656316</pub-id><?supplied-pmid 20831384?><pub-id pub-id-type="pmid">20831384</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louie</surname><given-names>JK</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Acosta</surname><given-names>M</given-names></name><name><surname>Yen</surname><given-names>C</given-names></name><name><surname>Samuel</surname><given-names>MC</given-names></name><name><surname>Schechter</surname><given-names>R</given-names></name><name><surname>Guevara</surname><given-names>H</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name></person-group><article-title>Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09</article-title><source>Clin Infect Dis</source><year>2012</year><volume>55</volume><fpage>1198</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1093/cid/cis636</pub-id><?supplied-pmid 22843781?><pub-id pub-id-type="pmid">22843781</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Bernstein</surname><given-names>HH</given-names></name><name><surname>Bradley</surname><given-names>JS</given-names></name><name><surname>Englund</surname><given-names>JA</given-names></name><name><surname>File</surname><given-names>TM</given-names></name><name><surname>Fry</surname><given-names>AM</given-names></name><name><surname>Gravenstein</surname><given-names>S</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Harper</surname><given-names>SA</given-names></name><name><surname>Hirshon</surname><given-names>JM</given-names></name><name><surname>Ison</surname><given-names>MG</given-names></name><name><surname>Johnston</surname><given-names>BL</given-names></name><name><surname>Knight</surname><given-names>SL</given-names></name><name><surname>McGeer</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>LE</given-names></name><name><surname>Wolfe</surname><given-names>CR</given-names></name><name><surname>Alexander</surname><given-names>PE</given-names></name><name><surname>Pavia</surname><given-names>AT</given-names></name></person-group><article-title>Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa</article-title><source>Clin Infect Dis</source><year>2019</year><volume>68</volume><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy874</pub-id><pub-id pub-id-type="pmid">30834445</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>SC</given-names></name><name><surname>Lam</surname><given-names>SW</given-names></name><name><surname>Neuner</surname><given-names>EA</given-names></name><name><surname>Bauer</surname><given-names>SR</given-names></name><name><surname>Bass</surname><given-names>SN</given-names></name></person-group><article-title>High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients</article-title><source>Intensive Care Med</source><year>2015</year><volume>41</volume><fpage>1365</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1007/s00134-015-3816-z</pub-id><?supplied-pmid 25952823?><pub-id pub-id-type="pmid">25952823</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Ngai</surname><given-names>KL</given-names></name><name><surname>Lui</surname><given-names>GC</given-names></name><name><surname>Wo</surname><given-names>SK</given-names></name><name><surname>Tam</surname><given-names>WW</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Wong</surname><given-names>BC</given-names></name><name><surname>Wong</surname><given-names>RY</given-names></name><name><surname>Choi</surname><given-names>KW</given-names></name><name><surname>Sin</surname><given-names>WW</given-names></name><name><surname>Lee</surname><given-names>EL</given-names></name><name><surname>Tomlinson</surname><given-names>B</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name></person-group><article-title>A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections</article-title><source>Clin Infect Dis</source><year>2013</year><volume>57</volume><fpage>1511</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1093/cid/cit597</pub-id><?supplied-pmid 24046309?><pub-id pub-id-type="pmid">24046309</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>ZR</given-names></name><name><surname>Bastin</surname><given-names>MLT</given-names></name><name><surname>Montgomery</surname><given-names>AA</given-names></name><name><surname>Flannery</surname><given-names>AH</given-names></name></person-group><article-title>Comparison of high-dose versus standard dose oseltamivir in critically ill patients with influenza</article-title><source>J Intensive Care Med</source><year>2017</year><volume>32</volume><fpage>574</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1177/0885066616638649</pub-id><?supplied-pmid 26992784?><pub-id pub-id-type="pmid">26992784</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>South East Asia Infectious Disease Clinical Research N</collab></person-group><article-title>Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial</article-title><source>BMJ</source><year>2013</year><volume>346</volume><fpage>f3039</fpage><pub-id pub-id-type="doi">10.1136/bmj.f3039</pub-id><pub-id pub-id-type="pmid">23723457</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaitre</surname><given-names>F</given-names></name><name><surname>Luyt</surname><given-names>CE</given-names></name><name><surname>Roullet-Renoleau</surname><given-names>F</given-names></name><name><surname>Nieszkowska</surname><given-names>A</given-names></name><name><surname>Zahr</surname><given-names>N</given-names></name><name><surname>Corvol</surname><given-names>E</given-names></name><name><surname>Fernandez</surname><given-names>C</given-names></name><name><surname>Antignac</surname><given-names>M</given-names></name><name><surname>Farinotti</surname><given-names>R</given-names></name><name><surname>Combes</surname><given-names>A</given-names></name></person-group><article-title>Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza</article-title><source>Ther Drug Monit</source><year>2012</year><volume>34</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e318248672c</pub-id><pub-id pub-id-type="pmid">22354159</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Wong</surname><given-names>KT</given-names></name><name><surname>Choi</surname><given-names>KW</given-names></name><name><surname>Joynt</surname><given-names>GM</given-names></name><name><surname>Lam</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Wong</surname><given-names>BC</given-names></name><name><surname>Lui</surname><given-names>GC</given-names></name><name><surname>Sin</surname><given-names>WW</given-names></name><name><surname>Wong</surname><given-names>RY</given-names></name><name><surname>Lam</surname><given-names>WY</given-names></name><name><surname>Yeung</surname><given-names>AC</given-names></name><name><surname>Leung</surname><given-names>TF</given-names></name><name><surname>So</surname><given-names>HY</given-names></name><name><surname>Yu</surname><given-names>AW</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name></person-group><article-title>Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia</article-title><source>Antivir Ther</source><year>2011</year><volume>16</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.3851/IMP1722</pub-id><pub-id pub-id-type="pmid">21447873</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behillil</surname><given-names>S</given-names></name><name><surname>May</surname><given-names>F</given-names></name><name><surname>Fourati</surname><given-names>S</given-names></name><name><surname>Luyt</surname><given-names>CE</given-names></name><name><surname>Chicheportiche</surname><given-names>T</given-names></name><name><surname>Sonneville</surname><given-names>R</given-names></name><name><surname>Tandjaoui-Lambiotte</surname><given-names>Y</given-names></name><name><surname>Roux</surname><given-names>D</given-names></name><name><surname>Guerin</surname><given-names>L</given-names></name><name><surname>Mayaux</surname><given-names>J</given-names></name><name><surname>Maury</surname><given-names>E</given-names></name><name><surname>Ferre</surname><given-names>A</given-names></name><name><surname>Georger</surname><given-names>JF</given-names></name><name><surname>Voiriot</surname><given-names>G</given-names></name><name><surname>Enouf</surname><given-names>V</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Mekontso</surname><given-names>DA</given-names></name><name><surname>de Prost</surname><given-names>N</given-names></name></person-group><article-title>Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study</article-title><source>Clin Infect Dis</source><year>2019</year><pub-id pub-id-type="doi">10.1093/cid/ciz904</pub-id><?supplied-pmid 31538643?><pub-id pub-id-type="pmid">31538643</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Vidal-Puigserver</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Merino</surname><given-names>E</given-names></name><name><surname>Garot</surname><given-names>D</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Jacobs</surname><given-names>F</given-names></name><name><surname>Rodriguez-Noriega</surname><given-names>E</given-names></name><name><surname>Husa</surname><given-names>P</given-names></name><name><surname>Shortino</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>HA</given-names></name><name><surname>Yates</surname><given-names>PJ</given-names></name><name><surname>Peppercorn</surname><given-names>AF</given-names></name></person-group><article-title>Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial</article-title><source>Lancet Respir Med</source><year>2017</year><volume>5</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(16)30435-0</pub-id><?supplied-pmid 28094141?><pub-id pub-id-type="pmid">28094141</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>MD</given-names></name><name><surname>Ison</surname><given-names>MG</given-names></name><name><surname>Monto</surname><given-names>AS</given-names></name><name><surname>Metev</surname><given-names>H</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>B</given-names></name><name><surname>Elder</surname><given-names>J</given-names></name><name><surname>McCullough</surname><given-names>A</given-names></name><name><surname>Collis</surname><given-names>P</given-names></name><name><surname>Sheridan</surname><given-names>WP</given-names></name></person-group><article-title>Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients</article-title><source>Clin Infect Dis</source><year>2014</year><volume>59</volume><fpage>e172</fpage><lpage>e185</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu632</pub-id><?supplied-pmid 25115871?><pub-id pub-id-type="pmid">25115871</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Shindo</surname><given-names>N</given-names></name></person-group><article-title>Influenza virus polymerase inhibitors in clinical development</article-title><source>Curr Opin Infect Diseases</source><year>2019</year><volume>32</volume><issue>2</issue><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000532</pub-id><pub-id pub-id-type="pmid">30724789</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ison</surname><given-names>MG</given-names></name><name><surname>Portsmouth</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Shishido</surname><given-names>T</given-names></name><name><surname>Hayden</surname><given-names>F</given-names></name><name><surname>Uehara</surname><given-names>T</given-names></name></person-group><article-title>LB16. Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 study)</article-title><source>Open Forum Infect Dis</source><year>2018</year><volume>5</volume><fpage>S764</fpage><lpage>S765</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofy229.2190</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>IFN</given-names></name><name><surname>To</surname><given-names>KKW</given-names></name><name><surname>Chan</surname><given-names>JFW</given-names></name><name><surname>Cheng</surname><given-names>VCC</given-names></name><name><surname>Liu</surname><given-names>KSH</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>TC</given-names></name><name><surname>Zhang</surname><given-names>AJ</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>TL</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Cheung</surname><given-names>MKS</given-names></name><name><surname>Leung</surname><given-names>W</given-names></name><name><surname>Lau</surname><given-names>JYN</given-names></name><name><surname>Fok</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial</article-title><source>Chest</source><year>2017</year><volume>151</volume><fpage>1069</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2016.11.012</pub-id><?supplied-pmid 27884765?><pub-id pub-id-type="pmid">27884765</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Loeches</surname><given-names>I</given-names></name><name><surname>Bermejo-Martin</surname><given-names>JF</given-names></name><name><surname>Valles</surname><given-names>J</given-names></name><name><surname>Granada</surname><given-names>R</given-names></name><name><surname>Vidaur</surname><given-names>L</given-names></name><name><surname>Vergara-Serrano</surname><given-names>JC</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Figueira</surname><given-names>JC</given-names></name><name><surname>Sirvent</surname><given-names>JM</given-names></name><name><surname>Blanquer</surname><given-names>J</given-names></name><name><surname>Suarez</surname><given-names>D</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Diaz</surname><given-names>E</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name></person-group><article-title>Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia</article-title><source>Intensive Care Med</source><year>2013</year><volume>39</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1007/s00134-013-2829-8</pub-id><?supplied-pmid 23344833?><pub-id pub-id-type="pmid">23344833</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Deeb</surname><given-names>AM</given-names></name><name><surname>Al-Hameed</surname><given-names>F</given-names></name><name><surname>Mandourah</surname><given-names>Y</given-names></name><name><surname>Almekhlafi</surname><given-names>GA</given-names></name><name><surname>Sindi</surname><given-names>AA</given-names></name><name><surname>Al-Omari</surname><given-names>A</given-names></name><name><surname>Shalhoub</surname><given-names>S</given-names></name><name><surname>Mady</surname><given-names>A</given-names></name><name><surname>Alraddadi</surname><given-names>B</given-names></name><name><surname>Almotairi</surname><given-names>A</given-names></name><name><surname>Al Khatib</surname><given-names>K</given-names></name><name><surname>Abdulmomen</surname><given-names>A</given-names></name><name><surname>Qushmaq</surname><given-names>I</given-names></name><name><surname>Solaiman</surname><given-names>O</given-names></name><name><surname>Al-Aithan</surname><given-names>AM</given-names></name><name><surname>Al-Raddadi</surname><given-names>R</given-names></name><name><surname>Ragab</surname><given-names>A</given-names></name><name><surname>Al Harthy</surname><given-names>A</given-names></name><name><surname>Kharaba</surname><given-names>A</given-names></name><name><surname>Jose</surname><given-names>J</given-names></name><name><surname>Dabbagh</surname><given-names>T</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><collab>Saudi Critical Care Trials g</collab></person-group><article-title>Macrolides in critically ill patients with Middle East Respiratory Syndrome</article-title><source>Int J Infect Dis</source><year>2019</year><volume>81</volume><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2019.01.041</pub-id><?supplied-pmid 30690213?><pub-id pub-id-type="pmid">30690213</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lian</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>BP</given-names></name><name><surname>Fontaine</surname><given-names>RE</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name></person-group><article-title>Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection</article-title><source>Clin Infect Dis</source><year>2011</year><volume>53</volume><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1093/cid/cir398</pub-id><?supplied-pmid 21810744?><pub-id pub-id-type="pmid">21810744</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>JW</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Adhikari</surname><given-names>NK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Jouvet</surname><given-names>P</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Griesdale</surname><given-names>D</given-names></name><name><surname>Burry</surname><given-names>LD</given-names></name><name><surname>Burns</surname><given-names>KE</given-names></name><name><surname>Hutchison</surname><given-names>J</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Menon</surname><given-names>K</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><collab>Canadian Critical Care Trials Group HNC</collab></person-group><article-title>The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness</article-title><source>Crit Care</source><year>2016</year><volume>20</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13054-016-1230-8</pub-id><?supplied-pmid 27036638?><pub-id pub-id-type="pmid">27036638</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>FE</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name><name><surname>Falsey</surname><given-names>AR</given-names></name></person-group><article-title>The effect of steroid use in hospitalized adults with respiratory syncytial virus-related illness</article-title><source>Chest</source><year>2011</year><volume>140</volume><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1378/chest.11-0047</pub-id><?supplied-pmid 21565965?><pub-id pub-id-type="pmid">21565965</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Allen Chan</surname><given-names>KC</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Ng</surname><given-names>EK</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Chiu</surname><given-names>RW</given-names></name><name><surname>Wong</surname><given-names>VW</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Wong</surname><given-names>KT</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Cockram</surname><given-names>CS</given-names></name><name><surname>Tam</surname><given-names>JS</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name></person-group><article-title>Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients</article-title><source>J Clin Virol</source><year>2004</year><volume>31</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.07.006</pub-id><?supplied-pmid 15494274?><pub-id pub-id-type="pmid">15494274</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Mandourah</surname><given-names>Y</given-names></name><name><surname>Al-Hameed</surname><given-names>F</given-names></name><name><surname>Sindi</surname><given-names>AA</given-names></name><name><surname>Almekhlafi</surname><given-names>GA</given-names></name><name><surname>Hussein</surname><given-names>MA</given-names></name><name><surname>Jose</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Al-Omari</surname><given-names>A</given-names></name><name><surname>Kharaba</surname><given-names>A</given-names></name><name><surname>Almotairi</surname><given-names>A</given-names></name><name><surname>Al Khatib</surname><given-names>K</given-names></name><name><surname>Alraddadi</surname><given-names>B</given-names></name><name><surname>Shalhoub</surname><given-names>S</given-names></name><name><surname>Abdulmomen</surname><given-names>A</given-names></name><name><surname>Qushmaq</surname><given-names>I</given-names></name><name><surname>Mady</surname><given-names>A</given-names></name><name><surname>Solaiman</surname><given-names>O</given-names></name><name><surname>Al-Aithan</surname><given-names>AM</given-names></name><name><surname>Al-Raddadi</surname><given-names>R</given-names></name><name><surname>Ragab</surname><given-names>A</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Al Harthy</surname><given-names>A</given-names></name><name><surname>Deeb</surname><given-names>AM</given-names></name><name><surname>Al Mutairi</surname><given-names>H</given-names></name><name><surname>Al-Dawood</surname><given-names>A</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><collab>Saudi Critical Care Trial G</collab></person-group><article-title>Corticosteroid therapy for critically ill patients with middle east respiratory syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2018</year><volume>197</volume><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1164/rccm.201706-1172OC</pub-id><?supplied-pmid 29161116?><pub-id pub-id-type="pmid">29161116</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name><name><surname>Hui</surname><given-names>KP</given-names></name><name><surname>Leung</surname><given-names>CY</given-names></name><name><surname>Uiprasertkul</surname><given-names>M</given-names></name><name><surname>Tipoe</surname><given-names>GL</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Ip</surname><given-names>NY</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name></person-group><article-title>Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection</article-title><source>J Infect Dis</source><year>2008</year><volume>198</volume><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1086/590499</pub-id><?supplied-pmid 18613795?><pub-id pub-id-type="pmid">18613795</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Hung IF, Wang To KK, Chan J, Chan KH, Yuen KY. ECCMID 2019. O0815 Treatment of severe influenza A infection with celecoxib. <ext-link ext-link-type="uri" xlink:href="https://www.escmid.org">https://www.escmid.org</ext-link>. Accessed 14 Sep 2019</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration</article-title><source>PLoS Pathog</source><year>2018</year><volume>14</volume><fpage>e1007428</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1007428</pub-id><?supplied-pmid 30422993?><pub-id pub-id-type="pmid">30422993</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CT</given-names></name><name><surname>Hung</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>CS</given-names></name><name><surname>He</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name></person-group><article-title>Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>4136</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-04365-6</pub-id><?supplied-pmid 28646236?><pub-id pub-id-type="pmid">28646236</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Chung</surname><given-names>FT</given-names></name><name><surname>Lin</surname><given-names>SM</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Chou</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Lin</surname><given-names>TY</given-names></name><name><surname>Kuo</surname><given-names>HP</given-names></name></person-group><article-title>Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure</article-title><source>Crit Care Med</source><year>2014</year><volume>42</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3182a2727d</pub-id><?supplied-pmid 24105455?><pub-id pub-id-type="pmid">24105455</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Laffey</surname><given-names>JG</given-names></name><name><surname>O&#x02019;Kane</surname><given-names>CM</given-names></name><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Mullan</surname><given-names>B</given-names></name><name><surname>Trinder</surname><given-names>TJ</given-names></name><name><surname>Johnston</surname><given-names>P</given-names></name><name><surname>Hopkins</surname><given-names>PA</given-names></name><name><surname>Johnston</surname><given-names>AJ</given-names></name><name><surname>McDowell</surname><given-names>C</given-names></name><name><surname>McNally</surname><given-names>C</given-names></name><collab>Investigators H-, Irish Critical Care Trials G</collab></person-group><article-title>Simvastatin in the acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>1695</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1403285</pub-id><?supplied-pmid 25268516?><pub-id pub-id-type="pmid">25268516</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Delucchi</surname><given-names>KL</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Hackett</surname><given-names>J</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>McDowell</surname><given-names>C</given-names></name><name><surname>Laffey</surname><given-names>JG</given-names></name><name><surname>O&#x02019;Kane</surname><given-names>CM</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><collab>Irish Critical Care Trials G</collab></person-group><article-title>Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial</article-title><source>Lancet Respir Med</source><year>2018</year><volume>6</volume><fpage>691</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30177-2</pub-id><?supplied-pmid 30078618?><pub-id pub-id-type="pmid">30078618</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Yan</surname><given-names>WW</given-names></name><name><surname>Chan</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Ngai</surname><given-names>CW</given-names></name><name><surname>Law</surname><given-names>KI</given-names></name><name><surname>Chow</surname><given-names>FL</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lai</surname><given-names>KY</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Lin</surname><given-names>CK</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection</article-title><source>Chest</source><year>2013</year><volume>144</volume><fpage>464</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1378/chest.12-2907</pub-id><?supplied-pmid 23450336?><pub-id pub-id-type="pmid">23450336</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Fern&#x000e1;ndez-Cruz</surname><given-names>E</given-names></name><name><surname>Markowitz</surname><given-names>N</given-names></name><name><surname>Pett</surname><given-names>S</given-names></name><name><surname>Babiker</surname><given-names>AG</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>Engen</surname><given-names>N</given-names></name><name><surname>Gordin</surname><given-names>F</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Kan</surname><given-names>V</given-names></name><name><surname>Polizzotto</surname><given-names>MN</given-names></name><name><surname>Riska</surname><given-names>P</given-names></name><name><surname>Ruxrungtham</surname><given-names>K</given-names></name><name><surname>Temesgen</surname><given-names>Z</given-names></name><name><surname>Lundgren</surname><given-names>J</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Davey</surname><given-names>RT</given-names></name><name><surname>Fern&#x000e1;ndez-Cruz</surname><given-names>E</given-names></name><name><surname>Markowitz</surname><given-names>N</given-names></name><name><surname>Pett</surname><given-names>S</given-names></name><name><surname>Babiker</surname><given-names>AG</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>Engen</surname><given-names>N</given-names></name><name><surname>Gordin</surname><given-names>F</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Kan</surname><given-names>V</given-names></name><name><surname>Polizzotto</surname><given-names>MN</given-names></name><name><surname>Riska</surname><given-names>P</given-names></name><name><surname>Ruxrungtham</surname><given-names>K</given-names></name><name><surname>Temesgen</surname><given-names>Z</given-names></name><name><surname>Lundgren</surname><given-names>J</given-names></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Butts</surname><given-names>J</given-names></name><name><surname>Denning</surname><given-names>E</given-names></name><name><surname>DuChene</surname><given-names>A</given-names></name><name><surname>Krum</surname><given-names>E</given-names></name><name><surname>Harrison</surname><given-names>M</given-names></name><name><surname>Meger</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>R</given-names></name><name><surname>Quan</surname><given-names>K</given-names></name><name><surname>Shaughnessy</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>G</given-names></name><name><surname>Vock</surname><given-names>D</given-names></name><name><surname>Metcalf</surname><given-names>J</given-names></name><name><surname>Dewar</surname><given-names>R</given-names></name><name><surname>Rehman</surname><given-names>T</given-names></name><name><surname>Natarajan</surname><given-names>V</given-names></name><name><surname>McConnell</surname><given-names>R</given-names></name><name><surname>Flowers</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Hoover</surname><given-names>M</given-names></name><name><surname>Coyle</surname><given-names>EM</given-names></name><name><surname>Munroe</surname><given-names>D</given-names></name><name><surname>Aagaard</surname><given-names>B</given-names></name><name><surname>Pearson</surname><given-names>M</given-names></name><name><surname>Cursley</surname><given-names>A</given-names></name><name><surname>Webb</surname><given-names>H</given-names></name><name><surname>Hudson</surname><given-names>F</given-names></name><name><surname>Russell</surname><given-names>C</given-names></name><name><surname>Sy</surname><given-names>A</given-names></name><name><surname>Purvis</surname><given-names>C</given-names></name><name><surname>Jackson</surname><given-names>B</given-names></name><name><surname>Collaco-Moraes</surname><given-names>Y</given-names></name><name><surname>Carey</surname><given-names>D</given-names></name><name><surname>Robson</surname><given-names>R</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>A</given-names></name><name><surname>Finley</surname><given-names>E</given-names></name><name><surname>Conwell</surname><given-names>D</given-names></name><name><surname>Losso</surname><given-names>MH</given-names></name><name><surname>Gambardella</surname><given-names>L</given-names></name><name><surname>Abela</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>P</given-names></name><name><surname>Alonso</surname><given-names>H</given-names></name><name><surname>Touloumi</surname><given-names>G</given-names></name><name><surname>Gioukari</surname><given-names>V</given-names></name><name><surname>Anagnostou</surname><given-names>O</given-names></name><name><surname>Avihingsanon</surname><given-names>A</given-names></name><name><surname>Pussadee</surname><given-names>K</given-names></name><name><surname>Ubolyam</surname><given-names>S</given-names></name><name><surname>Omotosho</surname><given-names>B</given-names></name><name><surname>Sol&#x000f3;rzano</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>T</given-names></name><name><surname>Vysyaraju</surname><given-names>K</given-names></name><name><surname>Rizza</surname><given-names>SA</given-names></name><name><surname>Whitaker</surname><given-names>JA</given-names></name><name><surname>Nahra</surname><given-names>R</given-names></name><name><surname>Baxter</surname><given-names>J</given-names></name><name><surname>Coburn</surname><given-names>P</given-names></name><name><surname>Gardner</surname><given-names>EM</given-names></name><name><surname>Scott</surname><given-names>JA</given-names></name><name><surname>Faber</surname><given-names>L</given-names></name><name><surname>Pastor</surname><given-names>E</given-names></name><name><surname>Makohon</surname><given-names>L</given-names></name><name><surname>MacArthur</surname><given-names>RA</given-names></name><name><surname>Hillman</surname><given-names>LM</given-names></name><name><surname>Farrough</surname><given-names>MJ</given-names></name><name><surname>Polenakovik</surname><given-names>HM</given-names></name><name><surname>Clark</surname><given-names>LA</given-names></name><name><surname>Colon</surname><given-names>RJ</given-names></name><name><surname>Kunisaki</surname><given-names>KM</given-names></name><name><surname>DeConcini</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Wolfe</surname><given-names>CR</given-names></name><name><surname>Mkumba</surname><given-names>L</given-names></name><name><surname>Carbonneau</surname><given-names>JY</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Fitzpatrick</surname><given-names>ME</given-names></name><name><surname>Kessinger</surname><given-names>CJ</given-names></name><name><surname>Salata</surname><given-names>RA</given-names></name><name><surname>Arters</surname><given-names>KA</given-names></name><name><surname>Tasi</surname><given-names>CM</given-names></name><name><surname>Panos</surname><given-names>RJ</given-names></name><name><surname>Lach</surname><given-names>LA</given-names></name><name><surname>Glesby</surname><given-names>MJ</given-names></name><name><surname>Ham</surname><given-names>KA</given-names></name><name><surname>Hughes</surname><given-names>VG</given-names></name><name><surname>Schooley</surname><given-names>RT</given-names></name><name><surname>Crouch</surname><given-names>D</given-names></name><name><surname>Muttera</surname><given-names>L</given-names></name><name><surname>Novak</surname><given-names>RM</given-names></name><name><surname>Bleasdale</surname><given-names>SC</given-names></name><name><surname>Zuckerman</surname><given-names>AE</given-names></name><name><surname>Manosuthi</surname><given-names>W</given-names></name><name><surname>Thaonyen</surname><given-names>S</given-names></name><name><surname>Chiewcharn</surname><given-names>T</given-names></name><name><surname>Suwanpimolkul</surname><given-names>G</given-names></name><name><surname>Gatechumpol</surname><given-names>S</given-names></name><name><surname>Bunpasang</surname><given-names>S</given-names></name><name><surname>Angus</surname><given-names>BJ</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Minton</surname><given-names>J</given-names></name><name><surname>Gkamaletsou</surname><given-names>MN</given-names></name><name><surname>Hambleton</surname><given-names>J</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Llewelyn</surname><given-names>MJ</given-names></name><name><surname>Sweetman</surname><given-names>J</given-names></name><name><surname>Carbone</surname><given-names>J</given-names></name><name><surname>Arribas</surname><given-names>JR</given-names></name><name><surname>Montejano</surname><given-names>R</given-names></name><name><surname>Lobo Beristain</surname><given-names>JL</given-names></name><name><surname>Martinez</surname><given-names>IZ</given-names></name><name><surname>Barberan</surname><given-names>J</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Dwyer</surname><given-names>DE</given-names></name><name><surname>Kok</surname><given-names>J</given-names></name><name><surname>Borges</surname><given-names>A</given-names></name><name><surname>Brandt</surname><given-names>CT</given-names></name><name><surname>Knudsen</surname><given-names>LS</given-names></name><name><surname>Sypsas</surname><given-names>N</given-names></name><name><surname>Constantinou</surname><given-names>C</given-names></name><name><surname>Markogiannakis</surname><given-names>A</given-names></name><name><surname>Zakynthinos</surname><given-names>S</given-names></name><name><surname>Katsaounou</surname><given-names>P</given-names></name><name><surname>Kalomenidis</surname><given-names>I</given-names></name><name><surname>Mykietiuk</surname><given-names>A</given-names></name><name><surname>Alzogaray</surname><given-names>MF</given-names></name><name><surname>Obed</surname><given-names>M</given-names></name><name><surname>Macias</surname><given-names>LM</given-names></name><name><surname>Ebensrtejin</surname><given-names>J</given-names></name><name><surname>Burgoa</surname><given-names>P</given-names></name><name><surname>Nannini</surname><given-names>E</given-names></name><name><surname>Lahitte</surname><given-names>M</given-names></name><name><surname>Perez-Patrigeon</surname><given-names>S</given-names></name><name><surname>Mart&#x000ed;nez-Orozco</surname><given-names>JA</given-names></name><name><surname>Ram&#x000ed;rez-Hinojosa</surname><given-names>JP</given-names></name></person-group><article-title>Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial</article-title><source>Lancet Respir Med.</source><year>2019</year><volume>7</volume><fpage>951</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(19)30253-X</pub-id><?supplied-pmid 31582358?><pub-id pub-id-type="pmid">31582358</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Aga</surname><given-names>E</given-names></name><name><surname>Elie-Turenne</surname><given-names>M-C</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>CL</given-names></name><name><surname>Metcalf</surname><given-names>JP</given-names></name><name><surname>Ozment</surname><given-names>C</given-names></name><name><surname>Raviprakash</surname><given-names>K</given-names></name><name><surname>Beeler</surname><given-names>J</given-names></name><name><surname>Holley</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name><surname>Warner</surname><given-names>S</given-names></name><name><surname>Chorley</surname><given-names>C</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Hughes</surname><given-names>MD</given-names></name><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Aga</surname><given-names>E</given-names></name><name><surname>Elie-Turenne</surname><given-names>M-C</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Tebas</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>CL</given-names></name><name><surname>Metcalf</surname><given-names>JP</given-names></name><name><surname>Ozment</surname><given-names>C</given-names></name><name><surname>Raviprakash</surname><given-names>K</given-names></name><name><surname>Beeler</surname><given-names>J</given-names></name><name><surname>Holley</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name><surname>Warner</surname><given-names>S</given-names></name><name><surname>Chorley</surname><given-names>C</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Hughes</surname><given-names>MD</given-names></name><name><surname>Davey</surname><given-names>RT</given-names></name><name><surname>Barron</surname><given-names>M</given-names></name><name><surname>Bastani</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>P</given-names></name><name><surname>Borkowsky</surname><given-names>W</given-names></name><name><surname>Cairns</surname><given-names>C</given-names></name><name><surname>Deville</surname><given-names>J</given-names></name><name><surname>Elie</surname><given-names>M-C</given-names></name><name><surname>Fichtenbaum</surname><given-names>C</given-names></name><name><surname>Finberg</surname><given-names>R</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Kaufman</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Maves</surname><given-names>R</given-names></name><name><surname>Morrow</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>M-H</given-names></name><name><surname>Park</surname><given-names>P</given-names></name><name><surname>Polk</surname><given-names>C</given-names></name><name><surname>Randolph</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Rubinson</surname><given-names>L</given-names></name><name><surname>Schofield</surname><given-names>C</given-names></name><name><surname>Shoham</surname><given-names>S</given-names></name><name><surname>Stalets</surname><given-names>E</given-names></name><name><surname>Stapleton</surname><given-names>RD</given-names></name></person-group><article-title>Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial</article-title><source>Lancet Respir Med.</source><year>2019</year><volume>7</volume><fpage>941</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(19)30199-7</pub-id><?supplied-pmid 31582360?><pub-id pub-id-type="pmid">31582360</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>AA</given-names><suffix>3rd</suffix></name><name><surname>Truwit</surname><given-names>JD</given-names></name><name><surname>Hite</surname><given-names>RD</given-names></name><name><surname>Morris</surname><given-names>PE</given-names></name><name><surname>DeWilde</surname><given-names>C</given-names></name><name><surname>Priday</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Thacker</surname><given-names>LR</given-names><suffix>2nd</suffix></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Brophy</surname><given-names>DF</given-names></name><name><surname>Sculthorpe</surname><given-names>R</given-names></name><name><surname>Nanchal</surname><given-names>R</given-names></name><name><surname>Syed</surname><given-names>A</given-names></name><name><surname>Sturgill</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>GS</given-names></name><name><surname>Sevransky</surname><given-names>J</given-names></name><name><surname>Kashiouris</surname><given-names>M</given-names></name><name><surname>Hamman</surname><given-names>S</given-names></name><name><surname>Egan</surname><given-names>KF</given-names></name><name><surname>Hastings</surname><given-names>A</given-names></name><name><surname>Spencer</surname><given-names>W</given-names></name><name><surname>Tench</surname><given-names>S</given-names></name><name><surname>Mehkri</surname><given-names>O</given-names></name><name><surname>Bindas</surname><given-names>J</given-names></name><name><surname>Duggal</surname><given-names>A</given-names></name><name><surname>Graf</surname><given-names>J</given-names></name><name><surname>Zellner</surname><given-names>S</given-names></name><name><surname>Yanny</surname><given-names>L</given-names></name><name><surname>McPolin</surname><given-names>C</given-names></name><name><surname>Hollrith</surname><given-names>T</given-names></name><name><surname>Kramer</surname><given-names>D</given-names></name><name><surname>Ojielo</surname><given-names>C</given-names></name><name><surname>Damm</surname><given-names>T</given-names></name><name><surname>Cassity</surname><given-names>E</given-names></name><name><surname>Wieliczko</surname><given-names>A</given-names></name><name><surname>Halquist</surname><given-names>M</given-names></name></person-group><article-title>Effect of vitamin c infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI Randomized clinical trial</article-title><source>JAMA</source><year>2019</year><volume>322</volume><fpage>1261</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.11825</pub-id><?supplied-pmid 31573637?><pub-id pub-id-type="pmid">31573637</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verweij</surname><given-names>PE</given-names></name><name><surname>Bruggemann</surname><given-names>RJM</given-names></name><name><surname>Wauters</surname><given-names>J</given-names></name><name><surname>Rijnders</surname><given-names>BJA</given-names></name><name><surname>Chiller</surname><given-names>T</given-names></name><name><surname>van de Veerdonk</surname><given-names>F</given-names></name></person-group><article-title>Influenza coinfection: be(a)ware of invasive aspergillosis</article-title><source>Clin Infect Dis</source><year>2019</year><volume>70</volume><fpage>349</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz391</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rochwerg</surname><given-names>B</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Elliott</surname><given-names>MW</given-names></name><name><surname>Hess</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>NS</given-names></name><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Navalesi</surname><given-names>PMOTSC</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Brozek</surname><given-names>J</given-names></name><name><surname>Conti</surname><given-names>G</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Guntupalli</surname><given-names>K</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Keenan</surname><given-names>S</given-names></name><name><surname>Mancebo</surname><given-names>J</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><collab>Raoof SMOTTF</collab></person-group><article-title>Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure</article-title><source>Eur Respir J</source><year>2017</year><volume>50</volume><fpage>1602426</fpage><pub-id pub-id-type="doi">10.1183/13993003.02426-2016</pub-id><?supplied-pmid 28860265?><pub-id pub-id-type="pmid">28860265</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Zarychanski</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Lacroix</surname><given-names>J</given-names></name><name><surname>Stelfox</surname><given-names>T</given-names></name><name><surname>Bagshaw</surname><given-names>S</given-names></name><name><surname>Choong</surname><given-names>K</given-names></name><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Turgeon</surname><given-names>AF</given-names></name><name><surname>Lapinsky</surname><given-names>S</given-names></name><name><surname>Ahern</surname><given-names>SP</given-names></name><name><surname>Smith</surname><given-names>O</given-names></name><name><surname>Siddiqui</surname><given-names>F</given-names></name><name><surname>Jouvet</surname><given-names>P</given-names></name><name><surname>Khwaja</surname><given-names>K</given-names></name><name><surname>McIntyre</surname><given-names>L</given-names></name><name><surname>Menon</surname><given-names>K</given-names></name><name><surname>Hutchison</surname><given-names>J</given-names></name><name><surname>Hornstein</surname><given-names>D</given-names></name><name><surname>Joffe</surname><given-names>A</given-names></name><name><surname>Lauzier</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Karachi</surname><given-names>T</given-names></name><name><surname>Wiebe</surname><given-names>K</given-names></name><name><surname>Olafson</surname><given-names>K</given-names></name><name><surname>Ramsey</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Dodek</surname><given-names>P</given-names></name><name><surname>Meade</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>R</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><collab>Canadian Critical Care Trials Group HNC</collab></person-group><article-title>Critically ill patients with 2009 influenza A(H1N1) infection in Canada</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1872</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1496</pub-id><?supplied-pmid 19822627?><pub-id pub-id-type="pmid">19822627</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Ferri</surname><given-names>C</given-names></name><name><surname>Martin-Loeches</surname><given-names>I</given-names></name><name><surname>Diaz</surname><given-names>E</given-names></name><name><surname>Masclans</surname><given-names>JR</given-names></name><name><surname>Gordo</surname><given-names>F</given-names></name><name><surname>Sole-Violan</surname><given-names>J</given-names></name><name><surname>Bodi</surname><given-names>M</given-names></name><name><surname>Aviles-Jurado</surname><given-names>FX</given-names></name><name><surname>Trefler</surname><given-names>S</given-names></name><name><surname>Magret</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>G</given-names></name><name><surname>Reyes</surname><given-names>LF</given-names></name><name><surname>Marin-Corral</surname><given-names>J</given-names></name><name><surname>Yebenes</surname><given-names>JC</given-names></name><name><surname>Esteban</surname><given-names>A</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Aliberti</surname><given-names>S</given-names></name><name><surname>Restrepo</surname><given-names>MI</given-names></name><collab>Grupo Espanol de Trabajo Gripe A Grave/Sociedad Espanola de Medicina Intensiva CyUCWG, investigators HNSWG</collab></person-group><article-title>Risk factors for noninvasive ventilation failure in critically ill subjects with confirmed influenza infection</article-title><source>Respir Care</source><year>2017</year><volume>62</volume><fpage>1307</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.4187/respcare.05481</pub-id><?supplied-pmid 28698265?><pub-id pub-id-type="pmid">28698265</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>TM</given-names></name><name><surname>Yam</surname><given-names>LY</given-names></name><name><surname>So</surname><given-names>LK</given-names></name><name><surname>Lau</surname><given-names>AC</given-names></name><name><surname>Poon</surname><given-names>E</given-names></name><name><surname>Kong</surname><given-names>BM</given-names></name><name><surname>Yung</surname><given-names>RW</given-names></name></person-group><article-title>Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome</article-title><source>Chest</source><year>2004</year><volume>126</volume><fpage>845</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1378/chest.126.3.845</pub-id><?supplied-pmid 15364765?><pub-id pub-id-type="pmid">15364765</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Guest</surname><given-names>CB</given-names></name><name><surname>Lapinsky</surname><given-names>SE</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name><name><surname>Louie</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>P</given-names></name><name><surname>Simor</surname><given-names>AE</given-names></name><name><surname>Stewart</surname><given-names>TE</given-names></name></person-group><article-title>Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>169</volume><fpage>1198</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1164/rccm.200305-715OC</pub-id><?supplied-pmid 14990393?><pub-id pub-id-type="pmid">14990393</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alraddadi</surname><given-names>BM</given-names></name><name><surname>Qushmaq</surname><given-names>I</given-names></name><name><surname>Al-Hameed</surname><given-names>FM</given-names></name><name><surname>Mandourah</surname><given-names>Y</given-names></name><name><surname>Almekhlafi</surname><given-names>GA</given-names></name><name><surname>Jose</surname><given-names>J</given-names></name><name><surname>Al-Omari</surname><given-names>A</given-names></name><name><surname>Kharaba</surname><given-names>A</given-names></name><name><surname>Almotairi</surname><given-names>A</given-names></name><name><surname>Al Khatib</surname><given-names>K</given-names></name><name><surname>Shalhoub</surname><given-names>S</given-names></name><name><surname>Abdulmomen</surname><given-names>A</given-names></name><name><surname>Mady</surname><given-names>A</given-names></name><name><surname>Solaiman</surname><given-names>O</given-names></name><name><surname>Al-Aithan</surname><given-names>AM</given-names></name><name><surname>Al-Raddadi</surname><given-names>R</given-names></name><name><surname>Ragab</surname><given-names>A</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Al Harthy</surname><given-names>A</given-names></name><name><surname>Sadat</surname><given-names>M</given-names></name><name><surname>Tlayjeh</surname><given-names>H</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name><collab>Saudi Critical Care Trials G</collab></person-group><article-title>Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome</article-title><source>Influenza Other Respir Viruses</source><year>2019</year><volume>13</volume><fpage>382</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1111/irv.12635</pub-id><?supplied-pmid 30884185?><pub-id pub-id-type="pmid">30884185</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>BK</given-names></name><name><surname>Wolfe</surname><given-names>KS</given-names></name><name><surname>Pohlman</surname><given-names>AS</given-names></name><name><surname>Hall</surname><given-names>JB</given-names></name><name><surname>Kress</surname><given-names>JP</given-names></name></person-group><article-title>Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial</article-title><source>JAMA</source><year>2016</year><volume>315</volume><fpage>2435</fpage><lpage>2441</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.6338</pub-id><?supplied-pmid 27179847?><pub-id pub-id-type="pmid">27179847</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frat</surname><given-names>JP</given-names></name><name><surname>Thille</surname><given-names>AW</given-names></name><name><surname>Mercat</surname><given-names>A</given-names></name><name><surname>Girault</surname><given-names>C</given-names></name><name><surname>Ragot</surname><given-names>S</given-names></name><name><surname>Perbet</surname><given-names>S</given-names></name><name><surname>Prat</surname><given-names>G</given-names></name><name><surname>Boulain</surname><given-names>T</given-names></name><name><surname>Morawiec</surname><given-names>E</given-names></name><name><surname>Cottereau</surname><given-names>A</given-names></name><name><surname>Devaquet</surname><given-names>J</given-names></name><name><surname>Nseir</surname><given-names>S</given-names></name><name><surname>Razazi</surname><given-names>K</given-names></name><name><surname>Mira</surname><given-names>JP</given-names></name><name><surname>Argaud</surname><given-names>L</given-names></name><name><surname>Chakarian</surname><given-names>JC</given-names></name><name><surname>Ricard</surname><given-names>JD</given-names></name><name><surname>Wittebole</surname><given-names>X</given-names></name><name><surname>Chevalier</surname><given-names>S</given-names></name><name><surname>Herbland</surname><given-names>A</given-names></name><name><surname>Fartoukh</surname><given-names>M</given-names></name><name><surname>Constantin</surname><given-names>JM</given-names></name><name><surname>Tonnelier</surname><given-names>JM</given-names></name><name><surname>Pierrot</surname><given-names>M</given-names></name><name><surname>Mathonnet</surname><given-names>A</given-names></name><name><surname>Beduneau</surname><given-names>G</given-names></name><name><surname>Deletage-Metreau</surname><given-names>C</given-names></name><name><surname>Richard</surname><given-names>JC</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Robert</surname><given-names>R</given-names></name><collab>Group FS, Network R</collab></person-group><article-title>High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>2185</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1503326</pub-id><?supplied-pmid 25981908?><pub-id pub-id-type="pmid">25981908</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Roca</surname><given-names>O</given-names></name><name><surname>Poulakou</surname><given-names>G</given-names></name><name><surname>Souto</surname><given-names>J</given-names></name><name><surname>Laborda</surname><given-names>C</given-names></name><name><surname>Balcells</surname><given-names>J</given-names></name><name><surname>Serra</surname><given-names>J</given-names></name><name><surname>Masclans</surname><given-names>JR</given-names></name><collab>Investigators C</collab></person-group><article-title>High-flow nasal therapy in adults with severe acute respiratory infection: a cohort study in patients with 2009 influenza A/H1N1v</article-title><source>J Crit Care</source><year>2012</year><volume>27</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2012.04.006</pub-id><?supplied-pmid 22762937?><pub-id pub-id-type="pmid">22762937</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Meade</surname><given-names>M</given-names></name><name><surname>Mercat</surname><given-names>A</given-names></name><name><surname>Brower</surname><given-names>RG</given-names></name><name><surname>Talmor</surname><given-names>D</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Pullenayegum</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Richard</surname><given-names>JC</given-names></name><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Bhatnagar</surname><given-names>N</given-names></name><name><surname>Stewart</surname><given-names>TE</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name></person-group><article-title>Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis</article-title><source>JAMA</source><year>2010</year><volume>303</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.218</pub-id><?supplied-pmid 20197533?><pub-id pub-id-type="pmid">20197533</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial I, Cavalcanti AB, Suzumura EA, Laranjeira LN, Paisani DM, Damiani LP, Guimaraes HP, Romano ER, Regenga MM, Taniguchi LNT, Teixeira C, Pinheiro de Oliveira R, Machado FR, Diaz-Quijano FA, Filho MSA, Maia IS, Caser EB, Filho WO, Borges MC, Martins PA, Matsui M, Ospina-Tascon GA, Giancursi TS, Giraldo-Ramirez ND, Vieira SRR, Assef M, Hasan MS, Szczeklik W, Rios F, Amato MBP, Berwanger O, Ribeiro de Carvalho CR, (2017) Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on Mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 318:1335&#x02013;1345</mixed-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boots</surname><given-names>RJ</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>Lassig-Smith</surname><given-names>M</given-names></name><name><surname>Stephens</surname><given-names>DP</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Shehabi</surname><given-names>Y</given-names></name><name><surname>Bass</surname><given-names>F</given-names></name><name><surname>Anthony</surname><given-names>A</given-names></name><name><surname>Long</surname><given-names>D</given-names></name><name><surname>Seppelt</surname><given-names>IM</given-names></name><name><surname>Weisbrodt</surname><given-names>L</given-names></name><name><surname>Erickson</surname><given-names>S</given-names></name><name><surname>Beca</surname><given-names>J</given-names></name><name><surname>Sherring</surname><given-names>C</given-names></name><name><surname>McGuiness</surname><given-names>S</given-names></name><name><surname>Parke</surname><given-names>R</given-names></name><name><surname>Stachowski</surname><given-names>ER</given-names></name><name><surname>Boyd</surname><given-names>R</given-names></name><name><surname>Howet</surname><given-names>B</given-names></name></person-group><article-title>Experience with high frequency oscillation ventilation during the 2009 H1N1 influenza pandemic in Australia and New Zealand</article-title><source>Anaesth Intensive Care</source><year>2011</year><volume>39</volume><fpage>837</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1177/0310057X1103900507</pub-id><?supplied-pmid 21970127?><pub-id pub-id-type="pmid">21970127</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Hand</surname><given-names>L</given-names></name><name><surname>Austin</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Matte</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Arroliga</surname><given-names>AC</given-names></name><name><surname>Stewart</surname><given-names>TE</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Meade</surname><given-names>MO</given-names></name><name><surname>Investigators</surname><given-names>OT</given-names></name><collab>Investigators OT, Canadian Critical Care Trials G</collab></person-group><article-title>High-frequency oscillation in early acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>795</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1215554</pub-id><?supplied-pmid 23339639?><pub-id pub-id-type="pmid">23339639</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>SE</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>MacKenzie</surname><given-names>I</given-names></name><name><surname>Tunnicliffe</surname><given-names>W</given-names></name><name><surname>Lall</surname><given-names>R</given-names></name><name><surname>Rowan</surname><given-names>K</given-names></name><name><surname>Cuthbertson</surname><given-names>BH</given-names></name><collab>Group OS</collab></person-group><article-title>High-frequency oscillation for acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>806</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1215716</pub-id><?supplied-pmid 23339638?><pub-id pub-id-type="pmid">23339638</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meade</surname><given-names>MO</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Hanna</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Bachman</surname><given-names>TE</given-names></name><name><surname>Bollen</surname><given-names>C</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Lamb</surname><given-names>SE</given-names></name><name><surname>Adhikari</surname><given-names>NKJ</given-names></name><name><surname>Mentzelopoulos</surname><given-names>SD</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Sud</surname><given-names>S</given-names></name><name><surname>Brower</surname><given-names>RG</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Stenzler</surname><given-names>A</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name></person-group><article-title>Severity of hypoxemia and effect of high-frequency oscillatory ventilation in acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2017</year><volume>196</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1164/rccm.201609-1938OC</pub-id><?supplied-pmid 28245137?><pub-id pub-id-type="pmid">28245137</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerin</surname><given-names>C</given-names></name><name><surname>Reignier</surname><given-names>J</given-names></name><name><surname>Richard</surname><given-names>JC</given-names></name><name><surname>Beuret</surname><given-names>P</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><name><surname>Boulain</surname><given-names>T</given-names></name><name><surname>Mercier</surname><given-names>E</given-names></name><name><surname>Badet</surname><given-names>M</given-names></name><name><surname>Mercat</surname><given-names>A</given-names></name><name><surname>Baudin</surname><given-names>O</given-names></name><name><surname>Clavel</surname><given-names>M</given-names></name><name><surname>Chatellier</surname><given-names>D</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Rosselli</surname><given-names>S</given-names></name><name><surname>Mancebo</surname><given-names>J</given-names></name><name><surname>Sirodot</surname><given-names>M</given-names></name><name><surname>Hilbert</surname><given-names>G</given-names></name><name><surname>Bengler</surname><given-names>C</given-names></name><name><surname>Richecoeur</surname><given-names>J</given-names></name><name><surname>Gainnier</surname><given-names>M</given-names></name><name><surname>Bayle</surname><given-names>F</given-names></name><name><surname>Bourdin</surname><given-names>G</given-names></name><name><surname>Leray</surname><given-names>V</given-names></name><name><surname>Girard</surname><given-names>R</given-names></name><name><surname>Baboi</surname><given-names>L</given-names></name><name><surname>Ayzac</surname><given-names>L</given-names></name><collab>Group PS</collab></person-group><article-title>Prone positioning in severe acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>2159</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214103</pub-id><?supplied-pmid 23688302?><pub-id pub-id-type="pmid">23688302</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Nong</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>A multicenter retrospective review of prone position ventilation (PPV) in treatment of severe human H7N9 avian flu</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0136520</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0136520</pub-id><?supplied-pmid 26317621?><pub-id pub-id-type="pmid">26317621</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papazian</surname><given-names>L</given-names></name><name><surname>Forel</surname><given-names>JM</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><name><surname>Penot-Ragon</surname><given-names>C</given-names></name><name><surname>Perrin</surname><given-names>G</given-names></name><name><surname>Loundou</surname><given-names>A</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Arnal</surname><given-names>JM</given-names></name><name><surname>Perez</surname><given-names>D</given-names></name><name><surname>Seghboyan</surname><given-names>JM</given-names></name><name><surname>Constantin</surname><given-names>JM</given-names></name><name><surname>Courant</surname><given-names>P</given-names></name><name><surname>Lefrant</surname><given-names>JY</given-names></name><name><surname>Guerin</surname><given-names>C</given-names></name><name><surname>Prat</surname><given-names>G</given-names></name><name><surname>Morange</surname><given-names>S</given-names></name><name><surname>Roch</surname><given-names>A</given-names></name><name><surname>Investigators</surname><given-names>AS</given-names></name></person-group><article-title>Neuromuscular blockers in early acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>1107</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1005372</pub-id><?supplied-pmid 20843245?><pub-id pub-id-type="pmid">20843245</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>National Heart</surname><given-names>L</given-names></name><name><surname>Blood Institute</surname><given-names>PCTN</given-names></name><name><surname>Moss</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Brower</surname><given-names>RG</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Ginde</surname><given-names>AA</given-names></name><name><surname>Gong</surname><given-names>MN</given-names></name><name><surname>Grissom</surname><given-names>CK</given-names></name><name><surname>Gundel</surname><given-names>S</given-names></name><name><surname>Hayden</surname><given-names>D</given-names></name><name><surname>Hite</surname><given-names>RD</given-names></name><name><surname>Hou</surname><given-names>PC</given-names></name><name><surname>Hough</surname><given-names>CL</given-names></name><name><surname>Iwashyna</surname><given-names>TJ</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>KD</given-names></name><name><surname>Talmor</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Ulysse</surname><given-names>CA</given-names></name><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name></person-group><article-title>Early neuromuscular blockade in the acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><fpage>1997</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1901686</pub-id><pub-id pub-id-type="pmid">31112383</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combes</surname><given-names>A</given-names></name><name><surname>Hajage</surname><given-names>D</given-names></name><name><surname>Capellier</surname><given-names>G</given-names></name><name><surname>Demoule</surname><given-names>A</given-names></name><name><surname>Lavoue</surname><given-names>S</given-names></name><name><surname>Guervilly</surname><given-names>C</given-names></name><name><surname>Da Silva</surname><given-names>D</given-names></name><name><surname>Zafrani</surname><given-names>L</given-names></name><name><surname>Tirot</surname><given-names>P</given-names></name><name><surname>Veber</surname><given-names>B</given-names></name><name><surname>Maury</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>Cohen</surname><given-names>Y</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Kalfon</surname><given-names>P</given-names></name><name><surname>Bouadma</surname><given-names>L</given-names></name><name><surname>Mehdaoui</surname><given-names>H</given-names></name><name><surname>Beduneau</surname><given-names>G</given-names></name><name><surname>Lebreton</surname><given-names>G</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name><name><surname>Mercat</surname><given-names>A</given-names></name><collab>Eolia Trial Group R, Ecmonet</collab></person-group><article-title>Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>1965</fpage><lpage>1975</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1800385</pub-id><?supplied-pmid 29791822?><pub-id pub-id-type="pmid">29791822</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goligher</surname><given-names>EC</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Hajage</surname><given-names>D</given-names></name><name><surname>Wijeysundera</surname><given-names>DN</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Juni</surname><given-names>P</given-names></name><name><surname>Brodie</surname><given-names>D</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Combes</surname><given-names>A</given-names></name></person-group><article-title>Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc bayesian analysis of a randomized clinical trial</article-title><source>JAMA</source><year>2018</year><volume>320</volume><fpage>2251</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.14276</pub-id><?supplied-pmid 30347031?><pub-id pub-id-type="pmid">30347031</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noah</surname><given-names>MA</given-names></name><name><surname>Peek</surname><given-names>GJ</given-names></name><name><surname>Finney</surname><given-names>SJ</given-names></name><name><surname>Griffiths</surname><given-names>MJ</given-names></name><name><surname>Harrison</surname><given-names>DA</given-names></name><name><surname>Grieve</surname><given-names>R</given-names></name><name><surname>Sadique</surname><given-names>MZ</given-names></name><name><surname>Sekhon</surname><given-names>JS</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Firmin</surname><given-names>RK</given-names></name><name><surname>Harvey</surname><given-names>C</given-names></name><name><surname>Cordingley</surname><given-names>JJ</given-names></name><name><surname>Price</surname><given-names>S</given-names></name><name><surname>Vuylsteke</surname><given-names>A</given-names></name><name><surname>Jenkins</surname><given-names>DP</given-names></name><name><surname>Noble</surname><given-names>DW</given-names></name><name><surname>Bloomfield</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>TS</given-names></name><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Menon</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>BL</given-names></name><name><surname>Rowan</surname><given-names>KM</given-names></name></person-group><article-title>Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1)</article-title><source>JAMA</source><year>2011</year><volume>306</volume><fpage>1659</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.1471</pub-id><pub-id pub-id-type="pmid">21976615</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshahrani</surname><given-names>MS</given-names></name><name><surname>Sindi</surname><given-names>A</given-names></name><name><surname>Alshamsi</surname><given-names>F</given-names></name><name><surname>Al-Omari</surname><given-names>A</given-names></name><name><surname>El Tahan</surname><given-names>M</given-names></name><name><surname>Alahmadi</surname><given-names>B</given-names></name><name><surname>Zein</surname><given-names>A</given-names></name><name><surname>Khatani</surname><given-names>N</given-names></name><name><surname>Al-Hameed</surname><given-names>F</given-names></name><name><surname>Alamri</surname><given-names>S</given-names></name><name><surname>Abdelzaher</surname><given-names>M</given-names></name><name><surname>Alghamdi</surname><given-names>A</given-names></name><name><surname>Alfousan</surname><given-names>F</given-names></name><name><surname>Tash</surname><given-names>A</given-names></name><name><surname>Tashkandi</surname><given-names>W</given-names></name><name><surname>Alraddadi</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Badawee</surname><given-names>M</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name></person-group><article-title>Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus</article-title><source>Ann Intensive Care</source><year>2018</year><volume>8</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s13613-017-0350-x</pub-id><?supplied-pmid 29330690?><pub-id pub-id-type="pmid">29330690</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF, Jr., Hite RD, Harabin AL, (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564&#x02013;2575</mixed-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>SM</given-names></name><name><surname>Pittman</surname><given-names>J</given-names></name><name><surname>Miller Iii</surname><given-names>RR</given-names></name><name><surname>Horton</surname><given-names>KD</given-names></name><name><surname>Markewitz</surname><given-names>B</given-names></name><name><surname>Hirshberg</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Grissom</surname><given-names>CK</given-names></name></person-group><article-title>Right and left heart failure in severe H1N1 influenza A infection</article-title><source>Eur Respir J</source><year>2011</year><volume>37</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1183/09031936.00008210</pub-id><?supplied-pmid 20516055?><pub-id pub-id-type="pmid">20516055</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Denison</surname><given-names>AM</given-names></name><name><surname>Bartlett</surname><given-names>JH</given-names></name><name><surname>Holman</surname><given-names>RC</given-names></name><name><surname>Deleon-Carnes</surname><given-names>M</given-names></name><name><surname>Emery</surname><given-names>SL</given-names></name><name><surname>Drew</surname><given-names>CP</given-names></name><name><surname>Shieh</surname><given-names>WJ</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name></person-group><article-title>Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection</article-title><source>J Infect Dis</source><year>2012</year><volume>205</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir861</pub-id><?supplied-pmid 22291193?><pub-id pub-id-type="pmid">22291193</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>JC</given-names></name><name><surname>Schwartz</surname><given-names>KL</given-names></name><name><surname>Campitelli</surname><given-names>MA</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Crowcroft</surname><given-names>NS</given-names></name><name><surname>Karnauchow</surname><given-names>T</given-names></name><name><surname>Katz</surname><given-names>K</given-names></name><name><surname>Ko</surname><given-names>DT</given-names></name><name><surname>McGeer</surname><given-names>AJ</given-names></name><name><surname>McNally</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Rosella</surname><given-names>LC</given-names></name><name><surname>Simor</surname><given-names>A</given-names></name><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Zahariadis</surname><given-names>G</given-names></name><name><surname>Gubbay</surname><given-names>JB</given-names></name></person-group><article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1702090</pub-id><?supplied-pmid 29365305?><pub-id pub-id-type="pmid">29365305</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chacko</surname><given-names>B</given-names></name><name><surname>Peter</surname><given-names>JV</given-names></name><name><surname>Pichamuthu</surname><given-names>K</given-names></name><name><surname>Ramakrishna</surname><given-names>K</given-names></name><name><surname>Moorthy</surname><given-names>M</given-names></name><name><surname>Karthik</surname><given-names>R</given-names></name><name><surname>John</surname><given-names>G</given-names></name></person-group><article-title>Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care</article-title><source>J Crit Care</source><year>2012</year><volume>27</volume><issue>106</issue><fpage>e101</fpage><lpage>e106</lpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohite</surname><given-names>PN</given-names></name><name><surname>Popov</surname><given-names>AF</given-names></name><name><surname>Bartsch</surname><given-names>A</given-names></name><name><surname>Zych</surname><given-names>B</given-names></name><name><surname>Dhar</surname><given-names>D</given-names></name><name><surname>Moza</surname><given-names>A</given-names></name><name><surname>Krueger</surname><given-names>H</given-names></name><name><surname>Simon</surname><given-names>AR</given-names></name></person-group><article-title>Successful treatment of novel H1N1 influenza related fulminant myocarditis with extracorporeal life support</article-title><source>J Cardiothorac Surg</source><year>2011</year><volume>6</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/1749-8090-6-164</pub-id><?supplied-pmid 22185401?><pub-id pub-id-type="pmid">22185401</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>K</given-names></name><name><surname>Cimon</surname><given-names>K</given-names></name><name><surname>Severn</surname><given-names>M</given-names></name><name><surname>Pessoa-Silva</surname><given-names>CL</given-names></name><name><surname>Conly</surname><given-names>J</given-names></name></person-group><article-title>Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e35797</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035797</pub-id><?supplied-pmid 22563403?><pub-id pub-id-type="pmid">22563403</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radonovich</surname><given-names>LJ</given-names><suffix>Jr</suffix></name><name><surname>Simberkoff</surname><given-names>MS</given-names></name><name><surname>Bessesen</surname><given-names>MT</given-names></name><name><surname>Brown</surname><given-names>AC</given-names></name><name><surname>Cummings</surname><given-names>DAT</given-names></name><name><surname>Gaydos</surname><given-names>CA</given-names></name><name><surname>Los</surname><given-names>JG</given-names></name><name><surname>Krosche</surname><given-names>AE</given-names></name><name><surname>Gibert</surname><given-names>CL</given-names></name><name><surname>Gorse</surname><given-names>GJ</given-names></name><name><surname>Nyquist</surname><given-names>AC</given-names></name><name><surname>Reich</surname><given-names>NG</given-names></name><name><surname>Rodriguez-Barradas</surname><given-names>MC</given-names></name><name><surname>Price</surname><given-names>CS</given-names></name><name><surname>Perl</surname><given-names>TM</given-names></name><name><surname>Pi</surname><given-names>Res</given-names></name></person-group><article-title>N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial</article-title><source>JAMA</source><year>2019</year><volume>322</volume><fpage>824</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.11645</pub-id><pub-id pub-id-type="pmid">31479137</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>M</given-names></name><name><surname>Dafoe</surname><given-names>N</given-names></name><name><surname>Mahony</surname><given-names>J</given-names></name><name><surname>John</surname><given-names>M</given-names></name><name><surname>Sarabia</surname><given-names>A</given-names></name><name><surname>Glavin</surname><given-names>V</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Earn</surname><given-names>DJ</given-names></name><name><surname>Chong</surname><given-names>S</given-names></name><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name></person-group><article-title>Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1865</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1466</pub-id><?supplied-pmid 19797474?><pub-id pub-id-type="pmid">19797474</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacIntyre</surname><given-names>CR</given-names></name><name><surname>Seale</surname><given-names>H</given-names></name><name><surname>Dung</surname><given-names>TC</given-names></name><name><surname>Hien</surname><given-names>NT</given-names></name><name><surname>Nga</surname><given-names>PT</given-names></name><name><surname>Chughtai</surname><given-names>AA</given-names></name><name><surname>Rahman</surname><given-names>B</given-names></name><name><surname>Dwyer</surname><given-names>DE</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>A cluster randomised trial of cloth masks compared with medical masks in healthcare workers</article-title><source>BMJ Open</source><year>2015</year><volume>5</volume><fpage>e006577</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2014-006577</pub-id><?supplied-pmid 25903751?><pub-id pub-id-type="pmid">25903751</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>R</given-names></name><name><surname>Nakaya</surname><given-names>T</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Daidoji</surname><given-names>T</given-names></name><name><surname>Bandou</surname><given-names>R</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Dohi</surname><given-names>O</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Konishi</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name></person-group><article-title>Situations leading to reduced effectiveness of current hand hygiene against infectious mucus from influenza virus-infected patients</article-title><source>mSphere</source><year>2019</year><volume>4</volume><fpage>e00474</fpage><lpage>e00479</lpage><?supplied-pmid 31533996?><pub-id pub-id-type="pmid">31533996</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">WHO public health research agenda for influenza. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/resources/research/en/">https://www.who.int/influenza/resources/research/en/</ext-link>. Last accessed Jan 4-2020</mixed-citation></ref></ref-list></back></article>